Releasable GLP-1 conjugates

Abstract

The present application provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein D is a residue of a GLP polypeptide or analog thereof, which undergo hydrolysis under physiological conditions to release the GLP polypeptide or analog thereof, and which are useful in the treatment of disorders that can be beneficially treated with a GLP polypeptide or analog thereof. [Formula 1]

Description

[Technical field]

[0001] Claiming priority This application claims priority to U.S. Provisional Patent Application No. 62 / 730,341, filed September 12, 2018, U.S. Provisional Patent Application No. 62 / 730,935, filed September 13, 2018, and U.S. Provisional Patent Application No. 62 / 771,972, filed November 27, 2018, the entire contents of which are incorporated herein by reference.

[0002] This document relates to conjugates of a glucagon-like peptide (GLP), such as a glucagon-like peptide 1 (GLP-1) polypeptide or an analog thereof (e.g., a GLP-1 analog), directly or indirectly bound to an aliphatic polymer (e.g., polyethylene glycol), where the GLP-1 polypeptide or analog thereof can be released from the conjugate in vivo. Such conjugates are referred to herein as "releasable GLP-1 conjugates." This document further includes methods and materials for making and using such releasable GLP-1 conjugates. [Background technology]

[0003] The World Health Organization estimated that over 400 million adults had diabetes in 2014, compared with 108 million in 1980 (1). 90% of these people had type 2 diabetes. This is not only related to population growth, but also to the increase in the age-standardized diabetes population from 4.7% to 8.5% of adults. Much of this is related to the increase in wealth in developing countries, including China and India, which is spent on diets that cause diabetes (e.g., consumption of sugary drinks) that also lead to weight gain and other medical problems such as cardiovascular disease. Cardiovascular complications are the leading cause of morbidity and mortality in these people (2). New treatments for diabetes are needed to combat the disease and its complications.

[0004] In general, diabetes and insulin treatments can be associated with weight gain, whereas glucagon-like peptide 1 receptor (GLP-1R) agonists are often associated with weight loss. This has led to increased interest in the treatment of weight gain, as well as the use of GLP-1R agonists in the treatment of diabetes. At least one GLP-1R agonist (liraglutide) has been approved for the treatment of both type 2 diabetes and obesity. Nearly one-third of the world's population (more than 2 billion people) can be considered obese or significantly overweight (7). In 2016, more than 340 million children and adolescents (ages 5-19) were overweight or obese (7). Obesity can often be treated with dietary modification, but some acute conditions, which are at risk for rapidly progressing to diabetes and severe disease, can benefit from pharmaceutical-assisted treatment.

[0005] The pharmacokinetic properties of proteins can be controlled by their conjugation to certain polymers, such as polyethylene glycol (PEG) (Fee and Van Alstine, Chemical Engineering Science, 61:924-934 (2006)). Several approaches to PEGylation of biologically active molecules have been described. However, in some cases, the presence of PEG (a hydrophilic polymer) significantly "blocks" the "surface area" of the conjugate, significantly inhibiting conjugate properties such as solubility (Fee and Van Alstine, Bioconjugate Chemistry, 2004 (15), 1304-1313). This can have adverse effects and offset any increase in circulation life, reduction in nonspecific proteolysis, or other enhanced properties resulting from PEGylation. An example for glucagon-like peptide-1 (GLP-1) is described in Lee et al., Bioconjugate Chem., 2006 (16), 377-382. In this example, the authors are able to covalently attach PEG2000 to GLP-1 through reactive amino groups at the amino terminus of the polypeptide (where natural proteolysis occurs and PEG inhibition of such proteolysis is beneficial) and through various lysine residues. PEG-lysine modified GLP-1 conjugates had insulinotropic activity similar to native GLP-1, while PEG-amino terminal modified GLP-1 conjugates showed reduced potency. Methods for designing, preparing, and using such releasable conjugates are provided herein. Summary of the Invention

[0006] Provided herein are conjugates of a glucagon-like-peptide (GLP), such as a glucagon-like peptide 1 (GLP-1) polypeptide or an analog thereof (e.g., a GLP-1 analog) indirectly (e.g., via a linking moiety) attached to an aliphatic polymer (e.g., polyethylene glycol, PEG), wherein the GLP polypeptide or an analog thereof can be released from the conjugate in vivo. In some embodiments, the GLP polypeptide or an analog thereof is a GLP-1 polypeptide or an analog thereof. Such conjugates are referred to herein as "releasable GLP-1 conjugates." This document further includes methods and materials for making and using such releasable GLP conjugates.

[0007] The releasable conjugates provided herein are based on the discovery that the 3' phosphotriester group of ribonucleosides is unstable in the presence of free vicinal 2' hydroxyl moieties and can be decomposed after intramolecular nucleophilic attack of the 2' hydroxyl moiety of the 3' phosphotriester group. The subsequent decomposition reaction is controlled by the attacking nucleophile and the phosphorus atom, with the vicinal configuration being the most reactive species, and the arabino geometry of the analogue is believed to be practically non-reactive. The conjugates provided herein advantageously provide the release of GLP-1 polypeptides or analogues from PEG or similar hydrophilic polymer-containing conjugates with little or no trace of pre-existing linkers and polymer systems on the GLP-1 polypeptides or analogues. One such example is shown in Scheme 1 as follows: Scheme 1 [ka]

[0008] In this example, cleavage of the trigger moiety, the E group, results in nucleophilic attack of the free hydroxyl on the phosphorus atom leading to the formation of a cyclic phosphotriester, a quinone methide, carbon dioxide (CO2), and a GLP-1 polypeptide or analog thereof. The cyclic phosphotriester can further hydrolyze at physiological pH, resulting in the opening of the five-membered ring and the formation of both isomeric phosphodiesters. The quinone methide can also further hydrolyze (e.g., react with water) at physiological pH to form 4-(hydroxymethyl)-phenol.

[0009] Such a system offers several advantages over alternative conjugates for releasing drugs. For example, the system is modifiable and cleavage can be altered based on the identity of the trigger moiety "E", as exemplified above. For example, E can contain an enzyme labile group, an acid labile functionality, or a pH labile functionality (e.g., base labile). Furthermore, because the E group is not directly attached to the polymer (e.g., polyethylene glycol), the need to significantly modify each E for every conjugate is avoided, and a basic form (underivatized) of any E moiety can be added to the conjugates described herein. In addition, the use of unsubstituted trigger groups offers the potential for better control over the kinetics of prodrug degradation and release of free biologically active molecules in vivo. Finally, the releasable conjugates provided herein offer substantial synthetic freedom. For example, looking at Scheme 1 above, in addition to the introduction of a phosphotriester to the 3' hydroxyl of the linker moiety, there is no need to have an E moiety selectively introduced to the 2' hydroxyl. In fact, the opposite configuration behaves similarly and both positional isomers are suitable and useful as releasable conjugates, either alone or in combination.

[0010] Compounds of formula (I) [ka] or a pharma- ceutically acceptable salt thereof, The aliphatic portion is a polymer, RP , and Polymer-L-(CH2) m - and polymer-L-(CH2-CH2-O) p -(CH2) m -, R P But, with any substitution C 1-6 Alkyl, optionally substituted C 1-3 Alkyl-O-(CH2-CH2-O) p -(CH2) m - and optionally substituted C 3-7 cycloalkyl; L is a linking group; m and p are each independently an integer from 1 to 10; D comprises a residue of a GLP-1 polypeptide or an analog thereof; Z 1 is O, S, and N(R N ), Z 3 is O and N(R N ) or Z 3 does not exist, A is O or N, and when A is O, R 3 does not exist, R N is H and optionally substituted C 1-6 alkyl, R 3 But H and C 1-6 alkyl; or R 3 and R 1 But A and R 1 together with the carbon atom to which it is attached form an optionally substituted 4- to 7-membered aliphatic heterocyclic ring; or R 3 and R 2 But, A, R 1 The carbon atom to which is bonded, and R 2 together with the carbon atom to which it is attached form an optionally substituted 4- to 8-membered aliphatic heterocyclic ring; M Ais a self-immolative group having any one of the formulae (a) to (i), [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 indicates the point of attachment to R 1 and R 2 are independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 aryl, and optionally substituted 5- to 14-membered heteroaryl; Or, R 1 and R 2 are bonded together with the carbon atom to which they are attached to an optionally substituted C 3-7 Cycloalkyl rings, optionally substituted 4- to 7-membered aliphatic heterocyclic rings, optionally substituted C 6-10 aryl, or an optionally substituted 5-14 membered heteroaryl; Or, R 1 and R 2 are linked together to form a ribose ring system, R 7 and R 8 but independently, H and C 1-6 alkyl, Provided herein are compounds or pharma- ceutically acceptable salts thereof, wherein E is a cleavable moiety.

[0011] Also, the compound of formula (II): [ka] or a pharma- ceutically acceptable salt thereof, The aliphatic portion is a polymer, R P , and Polymer-L-(CH2) m - and polymer-L-(CH2-CH2-O) p -(CH2) m -, RP But, with any substitution C 1-6 Alkyl, optionally substituted C 1-3 Alkyl-O-(CH2-CH2-O) p -(CH2) m - and optionally substituted C 3-7 cycloalkyl; L is a linking group; m and p are each independently an integer from 1 to 10; D comprises a residue of a biologically active drug; Z 1 is O, S, and N(R N ), Z 3 is O and N(R N ) or Z 3 does not exist, Z 4 is selected from O and S; A is O and N(R N ), R N is H and optionally substituted C 1-4 alkyl, M A is a diradical selected from i. A self-immolative group having any one of the formulae (a) to (i): [ka] And ii. A stable diradical selected from any one of formulas (j) to (l): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 indicates the point of attachment to R 1 and R 2 are independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10aryl, and optionally substituted 5- to 14-membered heteroaryl; Or, R 1 and R 2 are bonded together with the carbon atom to which they are attached to an optionally substituted C 3-7 Cycloalkyl rings, optionally substituted 4- to 7-membered aliphatic heterocyclic rings, optionally substituted C 6-10 aryl, or an optionally substituted 5-14 membered heteroaryl; Or, R 1 and R 2 are linked together to form a ribose ring system, R 7 and R 8 are independently H, C 1-6 Alkyl, amino, (C 1-6 Alkyl)amino, di-(C 1-6 alkyl)amino, acylamino, and protected amino groups; Also provided herein are compounds, or pharma- ceutically acceptable salts thereof, wherein E is a cleavable moiety.

[0012] Further provided herein is a pharmaceutical composition comprising a compound of Formula (I) or Formula (II), or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

[0013] The present disclosure also provides a method of treating a disease or condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or Formula (II), or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition described herein. In some embodiments, the disease or condition is selected from diabetes and obesity.

[0014] The present disclosure also provides a compound of the formula: [ka] or a pharma- ceutically acceptable salt thereof, wherein an aliphatic moiety, R 1 , R 2, A, E, and D are described herein.

[0015] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application pertains. Methods and materials are described herein for use in this application, and other suitable methods and materials known in the art can also be used. Materials, methods, and examples are merely illustrative and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references described herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, shall control.

[0016] Other features and advantages of the present application will become apparent from the following detailed description and figures, and from the claims. [Brief description of the drawings]

[0017] [Figure 1] 1 is a table showing the observed isoforms of liraglutide after digestion with the proteolytic enzyme dipeptidyl peptidase IV DPP-IV. [Diagram 2] 1 shows the spectra of 2.67 μM liraglutide and compound 7 after digestion with 50 mU / mL DPP-IV in 10 mM Na2HPO4 pH 7.6 at 37° C. for 15 hours. [Diagram 3] 1 shows exemplary data of extracted ion chromatogram (EIC) traces of full size liraglutide and liraglutide fragments in a sample liraglutide after digestion with DPP-IV for 96 hours at 37° C. and pH 7.4. [Figure 4] 1 is a line graph of the concentration of liraglutide in arbitrary units for liraglutide and compound 7 after digestion with 50 mU / mL DPP-IV in 10 mM Na2HPO4 pH 7.4 at 37° C. [Diagram 5]1 is a line graph of the concentration of liraglutide fragments shown in arbitrary units for liraglutide after digestion with 50 mU / mL DPP-IV in 10 mM Na2HPO4 pH 7.4 at 37° C. [Figure 6] 1 is a line graph of the concentration of liraglutide fragments in arbitrary units for compound 7 after digestion with 50 mU / mL DPP-IV in 10 mM Na2HPO4 pH 7.4 at 37° C. [Figure 7] 1 is a line graph of the concentration of the sum of all observed liraglutide fragments in arbitrary units for liraglutide and compound 7 after digestion with 50 mU / mL DPP-IV in 10 mM Na2HPO4 pH 7.4 at 37° C. [Figure 8] Non-limiting examples of GLP-1 analogs are provided. [Figure 9] 1 is a graph plotting the amount of liraglutide biological activity detected for the indicated amounts of liraglutide (SEQ ID NO:3) and compound 7. [Figure 10] 1 is a graph plotting the amount of liraglutide biological activity released from Compound 7 upon incubation in rat plasma for the indicated times. [Figure 11] Contains a graph plotting the amount of liraglutide (ng / mL) detected in pooled samples collected at the indicated times from rats administered liraglutide (SEQ ID NO:3, Group 1) or Compound 7 (Group 2). [Figure 12] FIG. 1 contains a graph plotting the amount of active liraglutide (nmol / L) detected in samples collected at the indicated times from rats administered liraglutide (SEQ ID NO:3, Group 1) or Compound 7 (Group 2). The half-life of each is provided. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] definition "C n-mThe term "alkyl" includes straight chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.) and branched chain alkyl groups (e.g., isopropyl, tert-butyl, isobutyl, etc.). In certain embodiments, a straight chain or branched chain alkyl has 12 or fewer carbon atoms in its backbone (e.g., C for straight chain). 1-12 ;C for branched chains 3-12 ). For example, C 1-12 The term includes alkyl groups containing 1 to 12 carbon atoms.

[0019] As used herein, "C n-m The term "alkylene," used alone or in combination with other terms, refers to a divalent alkyl linking group having n to m carbons. Examples of alkylene groups include, but are not limited to, ethane-1,1-diyl, ethane-1,2-diyl, propane-1,1,-diyl, propane-1,3-diyl, propane-1,2-diyl, butane-1,4-diyl, butane-1,3-diyl, butane-1,2-diyl, 2-methyl-propane-1,3-diyl, and the like. In some embodiments, the alkylene moiety contains 2 to 6, 2 to 4, 2 to 3, 1 to 6, 1 to 4, or 1 to 2 carbon atoms.

[0020] As used herein, "C n-m "Alkenyl" refers to an alkyl group having one or more double carbon-carbon bonds and having n to m carbons. Examples of alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms. "C n-m The term "alkenylene" refers to a divalent alkenyl linking group.

[0021] As used herein, "C n-mThe term "alkoxy," used alone or in combination with other terms, refers to a group of formula -O-alkyl, where the alkyl group has n to m carbons. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), butoxy (e.g., n-butoxy and tert-butoxy), and the like. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0022] As used herein, "C n-m The term "alkylamino" refers to a group of formula -NH(alkyl), where the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Examples of alkylamino groups include, but are not limited to, N-methylamino, N-ethylamino, N-propylamino (e.g., N-(n-propyl)amino and N-isopropylamino), N-butylamino (e.g., N-(n-butyl)amino and N-(tert-butyl)amino), and the like.

[0023] As used herein, "di(C n-m The term "-N(alkyl)amino" refers to a group of formula -N(alkyl)2, where the two alkyl groups each independently have n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0024] As used herein, the term "thio" refers to a group of the formula SH.

[0025] As used herein, the term "amino" refers to a group of formula -NH2.

[0026] As used herein, the term "carboxy" or "carboxyl" refers to the group -C(O)OH.

[0027] As used herein, "halo" or "halogen" refers to F, Cl, Br, or I. In some embodiments, halo is F, Cl, or Br. In some embodiments, halo is F or Cl.

[0028] The term "n-membered," where n is an integer, typically describes the number of ring-forming atoms in a moiety where n is the number of ring-forming atoms. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.

[0029] As used herein, "cycloalkyl" refers to non-aromatic cyclic hydrocarbons, including cyclized alkyl and / or alkenyl groups. Cycloalkyl groups can include monocyclic or polycyclic (e.g., having 2, 3, or 4 fused rings) groups and spiro rings. The ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo or sulfido (e.g., C(O) or C(S)). The definition of cycloalkyl also includes moieties having one or more aromatic rings fused to (i.e., having a bond in common with) a non-aromatic cyclic hydrocarbon, e.g., benzo or thienyl derivatives such as cyclopentane, cyclohexane, etc. Cycloalkyl groups containing fused aromatic rings can be bonded through any ring-forming atom, including the ring-forming atoms of the fused aromatic ring. Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 ring-forming atoms. In some embodiments, a cycloalkyl is a 3-12 membered monocyclic or bicyclic cycloalkyl. In some embodiments, a cycloalkyl is a C 3-7Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, cyclooctyl, cyclooctenyl, and the like. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, or cyclooctenyl. In some embodiments, cycloalkyl is a cyclooctenyl ring fused to one or two benzene rings. In some embodiments, cycloalkyl is a 3-8 membered or 3-7 membered monocyclic cycloalkyl group, such as C 3-8 or C 3-7 In some embodiments, the cycloalkyl is an 8-12 membered bicyclic cycloalkyl. In some embodiments, the cycloalkyl is an 8-16 membered bicyclic or tricyclic cycloalkyl (e.g., C 8-16 cycloalkyl).

[0030] As used herein, "heteroaryl" refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from sulfur, oxygen, and nitrogen. In some embodiments, the heteroaryl ring has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur, and oxygen. In some embodiments, any ring-forming N in the heteroaryl moiety can be an N-oxide. In some embodiments, the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur, and oxygen. In some embodiments, the heteroaryl is a 5-6 membered monocyclic heteroaryl having 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur, and oxygen. In some embodiments, the heteroaryl is a 5- or 6-membered heteroaryl ring. A 5-membered heteroaryl ring is a heteroaryl having a ring with 5 ring atoms, where one or more (e.g., 1, 2, or 3) ring atoms are independently selected from N, O, and S. Exemplary 5-membered heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl. A 6-membered heteroaryl ring is a heteroaryl having a ring with 6 ring atoms, one or more (e.g., 1, 2, or 3) ring atoms are independently selected from N, O, and S. Exemplary 6-membered heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl, and pyridazinyl. The term "heteroarylene" refers to a divalent heteroaryl linking group.

[0031] The term "aromatic" refers to a carbocyclic or heterocyclic ring having one or more polyunsaturated rings having aromatic character (i.e., having (4n+2) delocalized π (pi) electrons, where n is an integer).

[0032] The term "aliphatic" refers to organic compounds (including polymers) in which carbon atoms and heteroatoms form open chains and do not contain polyunsaturated rings having aromatic character. Aliphatic compounds can be linear or cyclic, saturated or unsaturated, straight-chain or branched.

[0033] As used herein, the term "polymer" refers to a macromolecule that contains multiple repeating subunits.

[0034] The term "aryl," used alone or in combination with other terms, refers to an aromatic hydrocarbon group that can be monocyclic or polycyclic (e.g., having 2, 3, or 4 fused rings). n-m The term "aryl" refers to an aryl group having n to m ring carbon atoms. Aryl groups include, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, an aryl group has from 6 to about 20 carbon atoms, from 6 to about 15 carbon atoms, or from 6 to about 10 carbon atoms. In some embodiments, an aryl group is phenyl. The term "arylene" refers to a divalent aryl linking group.

[0035] As used herein, "heterocycloalkyl" or "aliphatic heterocycle" refers to a non-aromatic monocyclic or polycyclic heterocycle having one or more ring-forming heteroatoms selected from O, N, or S. Monocyclic 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl groups are included in heterocycloalkyl. Heterocycloalkyl groups can also include spirocycles. Examples of heterocycloalkyl groups include pyrrolidin-2-one, 1,3-isoxazolidin-2-one, pyranyl, tetrahydrofuran, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, benzazapene, and the like. The ring-forming carbon atoms and heteroatoms of a heterocycloalkyl group may be optionally substituted with oxo or sulfido groups (e.g., C(O), S(O), C(S), or S(O)2, etc.). A heterocycloalkyl group may be bonded through a ring-forming carbon atom or ring-forming heteroatom. In some embodiments, a heterocycloalkyl group contains 0-3 double bonds. In some embodiments, a heterocycloalkyl group contains 0-2 double bonds. Also included within the definition of heterocycloalkyl are moieties having one or more aromatic rings fused to (i.e., having a bond in common with) a non-aromatic heterocycle, such as benzo or thienyl derivatives, such as piperidine, morpholine, azepines, etc. Heterocycloalkyl groups containing fused aromatic rings may be bonded through any ring-forming atom, including a ring-forming atom of the fused aromatic ring. In some embodiments, a heterocycloalkyl is a monocyclic 4-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur and having one or more oxidized ring members. In some embodiments, the heterocycloalkyl is a monocyclic or bicyclic 4-10 membered heterocycloalkyl having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur and having one or more oxidized ring members.In some embodiments, the heterocycloalkyl is an 8-12 membered heterocycloalkyl (e.g., a bicyclic heterocycloalkyl). In some embodiments, the heterocycloalkyl is an 8-16 membered heterocycloalkyl (e.g., a bicyclic or tricyclic heterocycloalkyl). In some embodiments, the 8-12 membered bicyclic heterocycloalkyl is an 8-12 membered fused heterocycloalkylaryl group or an 8-12 membered fused heterocycloalkylheteroaryl group. In some embodiments, the heterocycloalkyl is a 9-12 membered bicyclic heterocycloalkyl. In some embodiments, the 9-10 membered bicyclic heterocycloalkyl is a 9-10 membered fused heterocycloalkylaryl group or a 9-10 membered fused heterocycloalkylheteroaryl group. The term "heterocycloalkylene" refers to a divalent heterocycloalkyl linking group.

[0036] As used herein, the terms "individual" or "patient", used interchangeably, refer to any animal, including a mammal, preferably a mouse, rat, other rodent, rabbit, dog, cat, pig, cow, sheep, horse, or primate, most preferably a human.

[0037] As used herein, the phrase "therapeutically effective amount" refers to that amount of an active compound or pharmaceutical agent that elicits the biological or medical response in a tissue, system, animal, individual, or human that is being sought by a researcher, veterinarian, physician, or other clinician.

[0038] As used herein, the term "treat" or "treatment" refers to 1) preventing a disease: e.g., preventing a disease, condition, or disorder (i.e., halting further development of the pathology and / or symptomatology) in an individual experiencing or exhibiting the pathology or symptomatology of the disease, condition, or disorder, and / or 2) ameliorating a disease: e.g., ameliorating a disease, condition, disorder, or symptom (i.e., reversing the pathology and / or symptomatology) in an individual experiencing or exhibiting the pathology or symptomatology of the disease, condition, or disorder.

[0039] The terms "protecting group" and "protective group" refer to moieties that reversibly chemically modify a functional group to obtain chemoselectivity or reduce degradation in one or more subsequent chemical reactions. Suitable protecting groups are well known in the art (see, for example, Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein by reference in its entirety).

[0040] As used herein, the term "leaving group" refers to a molecule or molecular fragment (e.g., anion) that is displaced as a stable species with the bonding electrons in a chemical reaction. Examples of leaving groups include arylsulfonyloxy or alkylsulfonyloxy groups, such as mesylate or tosylate groups. Common anionic leaving groups also include halides such as Cl-, Br-, and I-.

[0041] As used herein, the term "ribose ring system" refers to an optionally substituted ribofuranose, arabinofuranose, xylofuranose, or lyxofuranose ring system, for example, having the general structure below: [ka]

[0042] In some embodiments, the ribose ring system comprises a portion of an optionally substituted ribonucleoside having the following structure: [ka]

[0043] In other embodiments, the ribose ring system comprises a portion of an optionally substituted lyxonucleoside having the following structure: [ka]

[0044] In some embodiments, the ribose ring system comprises a portion of an optionally substituted arabinonucleoside having the following structure: [ka]

[0045] In some embodiments, the ribose ring system comprises a portion of an optionally substituted xylonucleoside having the following structure: [ka]

[0046] In some embodiments, the nucleobase of a ribonucleoside, arabinonucleoside, xylonucleoside, or lyxonucleoside is adenine, cytosine, guanine, thymine, or uracil covalently linked at the 1' position to the ribose / lyxose ring.

[0047] As used herein, the term "self-immolative" refers to a moiety or residue that provides a stable bond formation between two groups of a compound or conjugate, but becomes unstable upon activation (e.g., nucleophilic attack), leading to rapid cleavage of the moiety or residue and separation of the two groups. The chemistry of self-immolative groups is described, for example, in Alouane, A. et al., "Self-immolative spacers: kinetic aspects, structure-property relationships, and applications", Angew.Chem.Int.Ed., 2015, 54, 7492-7509, and Kolakowski, RV et al., "The methylene alkoxy carbamate self-immolative unit: Utilization of the targeted delivery of alcohol-containing payloads with antibody-drug conjugates", Angew.Chem.Int.Ed., 2016, 55, 7948-7951.

[0048] As used herein, the term "optionally substituted" refers to a group (e.g., alkyl, cycloalkyl, alkylene, aryl, heteroaryl, etc.) in which one or more hydrogens on a designated atom, usually a carbon, oxygen, or nitrogen atom, may be replaced with a designated substituent, provided that the standard valence of the designated atom is not exceeded and the substitution results in a stable compound. When a substituent is keto or oxo (i.e., =O), two hydrogens on that atom are replaced. One or more of the substituents may be C 1-6 Alkyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, 4-7 membered heterocycloalkyl, substituted 5-14 membered heteroaryl, halo, CN, NO2, OR a , S.R. a , C(O)R a , C(O)NRa R a , C(O)OR a , O.C.(O)R a , O-C(O)NR a R a , N3, NHR a , N.R. a R a , N.R. a C(O)R a , N.R. a C(O)OR a , N.R. a C(O)NR a R a , N.R. a S(O)2R a , S(O)2R a , and S(O)NR a R a wherein each R a , H, C 1-6 Alkyl, C 3-7 Cycloalkyl, C 6-10 Aryl, 4-7 membered heterocycloalkyl, substituted 5-14 membered heteroaryl, C 1-4 Haloalkyl, C 2-6 Alkenyl, and C 2-6 alkynyl.

[0049] In some embodiments, one or more of the optional substituents is C 1-6 Alkyl, C 1-4 It is selected from haloalkyl, OH, NO2, CN, and acetyl.

[0050] In some embodiments, the optional substituent is SH.

[0051] In some embodiments, the optional substituent is azide (N3).

[0052] In some embodiments, the optional substituent is a group of the formula: [ka]

[0053] In some embodiments, the optional substituent is a maleimide of the formula: [ka]

[0054] In some embodiments, the optional substituent is a cyclooctyne, such as dibenzocyclooctyne (DBCO), difluorobenzocyclooctyne (DIFBO), biarylazacyclooctyne (BARAC), dibenzocyclooctyne (DIBO), difluorinated cyclooctyne (DIFO), monofluorinated cyclooctyne (MOFO), dimethoxyazacyclooctyne (DIMAC), or aryl-less octyne (ALO), each of which is optionally substituted with 1, 2, 3, 4, or 5 of any of the substituents described herein.

[0055] In some embodiments, the optional substituent is a cyclooctyne selected from the group consisting of: [ka]

[0056] As used herein, the term "about" is meant to account for variations due to experimental error. As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0057] compound Compounds of formula (I) In one general aspect, the application relates to a compound of formula (I): [ka] or a pharma- ceutically acceptable salt thereof, wherein: The aliphatic portion is a polymer, R P , and Polymer-L-(CH2) m- and polymer-L-(CH2-CH2-O) p -(CH2) m -, R P But, with any substitution C 1-6 Alkyl, optionally substituted C 1-3 Alkyl-O-(CH2-CH2-O) p -(CH2) m - and optionally substituted C 3-7 cycloalkyl; L is a linking group; m and p are each independently an integer from 1 to 10; D comprises a residue of a GLP-1 polypeptide or an analog thereof; Z 1 is O, S, and N(R N ), Z 3 is O and N(R N ) or Z 3 does not exist, A is O or N, and when A is O, R 3 does not exist, R N is H and optionally substituted C 1-6 alkyl, R 3 But H and C 1-6 alkyl; or R 3 and R 1 But A and R 1 together with the carbon atom to which it is attached form an optionally substituted 4- to 7-membered aliphatic heterocyclic ring; or R 3 and R 2 But, A, R 1 The carbon atom to which is bonded, and R 2 together with the carbon atom to which it is attached form an optionally substituted 4- to 8-membered aliphatic heterocyclic ring; M A is a self-immolative group having any one of the formulae (a) to (i), [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 indicates the point of attachment to R 1 and R 2 are independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 aryl, and optionally substituted 5- to 14-membered heteroaryl; Or, R 1 and R 2 are bonded together with the carbon atom to which they are attached to an optionally substituted C 3-7 Cycloalkyl rings, optionally substituted 4- to 7-membered aliphatic heterocyclic rings, optionally substituted C 6-10 aryl, or an optionally substituted 5-14 membered heteroaryl; Or, R 1 and R 2 are linked together to form a ribose ring system, R 7 and R 8 but independently, H and C 1-6 alkyl, E is a cleavable moiety.

[0058] In some embodiments of Formula (I), R P , L, m, p, D, Z 1 , Z 3 , A, R N , M A , R 1 , R 2 , R 7 , R 8 and E are as described herein for compounds of formula (I), R 3 H and C 1-6 alkyl; or R 3 and R 1 But A and R 1together with the carbon atom to which it is attached form an optionally substituted 4- to 7-membered aliphatic heterocyclic ring; or R 3 and R 2 But, A, R 1 The carbon atom to which is bonded, and R 2 together with the carbon atom to which it is attached form an optionally substituted 4- to 8-membered aliphatic heterocyclic ring.

[0059] In some embodiments of Formula (I), A is N. In other embodiments, A is O.

[0060] In some embodiments of Formula (I), A is NR 3 It is.

[0061] In some embodiments of Formula (I), A is NR 3 If R 3 and R 1 A and R 1 together with the carbon atom to which it is attached to form an optionally substituted 4-7 membered aliphatic heterocyclic ring. In some aspects of these embodiments, the 4-7 membered aliphatic heterocyclic ring is selected from the group consisting of: [ka] where x indicates the point of attachment to E and y indicates R 1 indicates the point of attachment to the carbon atom to which it is bonded.

[0062] In some embodiments of Formula (I), A is NR 3 If R 3 and R 2 A, R 1 The carbon atom to which is bonded, and R 2 together with the carbon atom to which it is attached form an optionally substituted 4- to 8-membered aliphatic heterocyclic ring.

[0063] In some embodiments, the compound of formula (I) has any one of the following formulae: [ka] JPEG0007675648000020.jpg190166 or a pharma- ceutically acceptable salt thereof.

[0064] In some embodiments, the compound of formula (I) is any one of the compounds of formula (II) described herein.

[0065] Compound of formula (II) In one general aspect, the application relates to a compound of formula (II): [ka] or a pharma- ceutically acceptable salt thereof, wherein: The aliphatic portion is a polymer, R P , and Polymer-L-(CH2) m - and polymer-L-(CH2-CH2-O) p -(CH2) m -, R P But, with any substitution C 1-6 Alkyl, optionally substituted C 1-3 Alkyl-O-(CH2-CH2-O) p -(CH2) m - and optionally substituted C 3-7 cycloalkyl; L is a linking group; m and p are each independently an integer from 1 to 10; D comprises a residue of a GLP-1 polypeptide or an analog thereof; Z 1 is O, S, and N(R N ), Z 3 is O and N(R N ) or Z 3 does not exist, Z 4 is selected from O and S; A is O and N(RN ), R N is H and optionally substituted C 1-4 alkyl, M A is a diradical selected from a) a self-immolative group having any one of the formulae (a) to (i): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 indicates the point of attachment to, and b) A stable diradical selected from any one of formulas (j) to (l): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 indicates the point of attachment to R 1 and R 2 are independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 aryl, and optionally substituted 5- to 14-membered heteroaryl; Or, R 1 and R 2 are bonded together with the carbon atom to which they are attached to an optionally substituted C 3-7 Cycloalkyl rings, optionally substituted 4- to 7-membered aliphatic heterocyclic rings, optionally substituted C 6-10 aryl, or an optionally substituted 5-14 membered heteroaryl; Or, R 1 and R 2 are linked together to form a ribose ring system, R 7 and R 8 are independently H, C 1-6 Alkyl, amino, (C 1-6 Alkyl)amino, di-(C 1-6alkyl)amino, acylamino, and protected amino groups; E is a cleavable moiety.

[0066] In some embodiments of Formula (I) or Formula (II), the aliphatic moiety is a polymer, R P and the formula polymer-L-(CH2) m - is selected from the group P is an arbitrarily substituted C 1-6 Alkyl and optionally substituted C 3-7 cycloalkyl, and m is an integer from 1 to 10.

[0067] In some embodiments of formula (I) or formula (II), D comprises a residue of any one of the GLP-1 polypeptides or analogs thereof described herein (e.g., D comprises a residue of liraglutide). In some embodiments of formula (I) or formula (II), D is a residue of any one of the GLP-1 polypeptides or analogs thereof described herein (e.g., D is a residue of liraglutide).

[0068] In some embodiments of Formula (I) or Formula (II), the aliphatic moiety has the formula: polymer-L-(CH) m In some aspects of these embodiments, L is a linking group that includes a heterocycloalkylene or heteroarylene. For example, L is a linking group that includes a succinimide or triazole. In some embodiments, L is a linking group of any one of the following formulae: [ka] During the ceremony, [ka] indicates the point of attachment of the linking group to the polymer or CH2 group.

[0069] In some embodiments, the linking group L is a linking group of the formula: [ka] During the ceremony, [ka] indicates the point of attachment of the linking group to the polymer or CH2 group.

[0070] In some embodiments, L is of the formula (L 1 ) group, [ka] wherein ring C is an optionally substituted C 8-16 selected from the group consisting of cycloalkyl and optionally substituted 8- to 16-membered heterocycloalkyl; [ka] indicates the point of attachment of the linking group to the polymer or to the CH2 group. In some aspects of these embodiments, C 8-16 Cycloalkyl is cyclooctenyl, optionally fused to one or two benzene rings. In other aspects of these embodiments, C 8-16 Cycloalkyl is a halogen, OH, C 1-3 Alkyl, and C 1-3 and cyclooctenyl optionally substituted with one, two, or three substituents selected from alkoxy. For example, cyclooctenyl can be substituted with one or two fluoro or one or two methoxy groups.

[0071] In some embodiments, the formula (L 1 ) group is selected from any one of the following formulae: [ka]

[0072] In some embodiments, the formula (L 1 ) is a group [ka]

[0073] In some embodiments, the formula (L 1 ) is a group [ka]

[0074] In some embodiments, the formula (L 1 ) is a group [ka] It is.

[0075] In some embodiments, the formula (L 1 ) is a group [ka] It is.

[0076] In some embodiments, the formula (L 1 ) is a group [ka] It is.

[0077] In some embodiments, the formula (L 1 ) is a group [ka] It is.

[0078] In some embodiments, m is an integer from 1 to 6. For example, m is 1, 2, 3, 4, 5, or 6. In some embodiments, m is an integer from 1 to 4.

[0079] In some embodiments, the aliphatic moiety is any one of the following formulas: [ka]

[0080] In some embodiments, the aliphatic moiety is any one of the following formulas: [ka]

[0081] In some embodiments of formula (I) or formula (II), the aliphatic portion is a polymer (e.g., any one of the polymers described herein). The polymer of the aliphatic portion can be selected from poly(alkylene glycol), poly(oxyethylated polyol), poly(olefinic alcohol), poly(α-hydroxy acid), poly(vinyl alcohol), polyoxazoline, or copolymers thereof. In some embodiments, the polymer of the aliphatic portion is polyethylene glycol. For example, the aliphatic portion comprises linear polyethylene glycol or branched polyethylene glycol.

[0082] In some embodiments of Formula (I) or Formula (II), the aliphatic moiety is R P In some embodiments, R P is an arbitrarily substituted C 1-6 Alkyl or optionally substituted C 3-7 Cycloalkyl. For example, R P is C 1-6 Alkyl, C 1-6 Cyanoalkyl, and C 3-7 cycloalkyl. The aliphatic moiety is selected from R P If the aliphatic moiety is C 1-6 It can be alkyl (e.g., methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, amyl, or hexyl). For example, the aliphatic moiety can be cyanoethyl. In some embodiments, the aliphatic moiety can be 2-cyanoethyl. In other embodiments, the aliphatic moiety can be C 3-7 cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl). In some embodiments, R Pis isopropyl. In some embodiments, R P is cyanoethyl.

[0083] In some embodiments, R P is selected from any one of the groups of the following formulae: [ka]

[0084] In some embodiments, R P is selected from any one of the groups of the following formulae: [ka]

[0085] In some embodiments, R P is the substituted C of the following formula: 1-6 is alkyl, [ka] In the formula, p is an integer from 1 to 6. For example, p is 1, 2, 3, 4, 5, or 6. In some embodiments, p is an integer from 1 to 4.

[0086] In some embodiments, R P is selected from any one of the following formulas: [ka]

[0087] In some embodiments, R P is selected from any one of the following formulas: [ka]

[0088] In some embodiments, R P teeth, [ka] It is.

[0089] In some embodiments, R P teeth, [ka] and In the formula, p is an integer of 1 to 6.

[0090] In some embodiments of Formula (I) or Formula (II), Z 1 is O, S, and N(R N In some embodiments, Z 1 is O. In some embodiments, Z 1 is NH. In some embodiments, Z 1 is N(C 1-6 In some embodiments, Z 1 is S.

[0091] In some embodiments of Formula (I) or Formula (II), Z 3 is O and N(R N In some embodiments, Z 3 is absent. In some embodiments, Z 3 is O. In some embodiments, Z 3 is NH. In some embodiments, Z 3 is N(C 1-6 alkyl).

[0092] In some embodiments of Formula (I) or Formula (II), Z 1 is O and Z 3 is NH. In some embodiments, Z 1 is NH and Z 3 is O. In some embodiments, Z 1 is O and Z 3 is absent. In some embodiments, Z 1 is O and Z3 is O. In some embodiments, Z 1 is NH and Z 3 is NH. In some embodiments, Z 1 is NH and Z 3 is absent. In some embodiments, Z 1 is S and Z 3 is O. In some embodiments, Z 1 is S and Z 3 is NH. In some embodiments, Z 1 is S and Z 3 does not exist.

[0093] In some embodiments of Formula (I), Z 4 is O. In another embodiment of formula (I), Z 4 is S.

[0094] In some embodiments of Formula (I) or Formula (II), M A is a diradical, which may be used alone or together with Z 1 together with M upon nucleophilic attack on the phosphorus atom in formula (I) or formula (II). A (Z 3 -D) are characterized as making better leaving groups than any one of the aliphatic moieties described herein. For example, as shown in Scheme 2 below, upon nucleophilic attack on the phosphorus atom by the 2' hydroxyl group of the ribose unit, both the 2-hydroxypropionate and the polyethylene glycol fragment make equally good leaving groups, and the nucleophilic displacement reaction is nonselective. Scheme 2 [ka]

[0095] In contrast, in some embodiments of formula (I) or formula (II) described herein, -Z 1 -M AGroups containing -Z fragments are better leaving groups than aliphatic moieties (e.g., polyethylene glycol), such that upon nucleophilic attack on the phosphorus atom by the 2' hydroxyl group of the ribose unit under similar conditions as compared to Scheme 2, the polyethylene glycol fragment remains covalently attached to the phosphorus atom, and -Z 1 -M A The group containing the -fragment is selectively cleaved.

[0096] In some embodiments of Formula (I) or Formula (II), M A is a diradical, which may be used alone or together with Z 1 together with M upon nucleophilic attack on the phosphorus atom in formula (I) or formula (II). A (Z 3 -D) creates a better leaving group than polyethylene glycol. In some embodiments, 1 -M A -Z 3 -Z represented by D 1 -M A -Z 3 The conjugate acid of the -D moiety has a lower pKa value than the conjugate acid of the aliphatic moiety conjugated to the compound of Formula (I) or Formula (II). 1 -M A -Z 3 The D group has a lower pKa value than the polyethylene glycol or alcohol. In some aspects of these embodiments, Z 1 is oxygen, M A contains an aromatic moiety (e.g., M A In some embodiments, Z includes phenylene. 1 is nitrogen, M A contains an aromatic moiety (e.g., M A includes phenylene), the formula HZ 1 -M A -Z 3 The conjugate base of the -D compound is M A Z to the aromatic ring of 1 Due to the delocalization of the lone pair on the nitrogen atom of is a better leaving group than any one of the aliphatic moieties described herein.

[0097] In some embodiments, the compound of Formula (I) or Formula (II) contains a single sacrificial functional group. In some embodiments of Formula (I) or Formula (II), M A is a self-immolative group. In some embodiments, M A is any one of the self-immolative groups described, for example, in Alouane, A. et al., "Self-immolative spacers: kinetic aspects, structure-property relationships, and applications", Angew. Chem. Int. Ed., 2015, 54, 7492-7509. In other embodiments, M A is, for example, any one of the self-immolative groups described in Kolakowski, R. et al., “The Methylene Alkoxy Carbamate Self-Immolative Unit: Utilization for the Targeted Delivery of Alcohol-Containing Payloads with Antibody-Drug Conjugates”, Angew. Chem. Int. Ed., 2016, 55(28), 7948-7951.

[0098] In some embodiments, M A is a self-immolative group having any one of the formulae (a) to (i), [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 The attachment points to the

[0099] In some embodiments of Formula (I) or Formula (II), the self-immolative group is PZ 1 Bond cleavage produces a cascade of decomposition reactions (e.g., the hydrolysis cascade described herein), ultimately resulting in i)Z 3 Compound HZ in the presence3 -D release of the conjugate base, or ii) Z 3 resulting in the release of the conjugate base of the compound HO-(C=O)-D in the absence of

[0100] In some embodiments, the formula HZ 3 The conjugate base of the compound of formula - Z 3 In some embodiments, the conjugate base of the compound of formula HO-(C=O)-D is a moiety of the formula - The O-(C=O)-D part.

[0101] In some embodiments of Formula (I) or Formula (II), Z 3 exists (e.g., Z 3 is O or NH, M A is a self-immolative group. In some embodiments, the self-immolative group is PZ 1 Bond cleavage produces a cascade of decomposition reactions, ultimately resulting in the compound HZ 3 -D resulting in the release of the conjugate base.

[0102] In some aspects of these embodiments, PZ 1 The bond is broken by Z 1 =M A’ , CO2, and compound HZ 3 -D, where M A’ is a fragment of a self-immolative group (e.g., a self-immolative group of any of formulae (a)-(g)) lacking the moiety of the formula: [ka]

[0103] In one example, M A is a self-immolative group of formula (b), M A’ is a fragment of the formula [ka] In the formula, x is Z 1indicates the point of attachment to Z 3 The attachment points to the

[0104] In one example, M A is a self-immolative group of formula (b), M A’ is a fragment of the formula [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 The attachment points to the

[0105] In one example, M A is a self-immolative group of formula (d), M A’ is a fragment of the formula [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 The attachment points to the

[0106] In some embodiments, Z 1 But, M A’ In the compound, Z 1 and M. A’ The second bond between 1 And, M. A’ Connects any one of the atoms in the group. For example, M A is a self-immolative group of formula (a), Z 1 and M. A’ The second bond between Z 1 And Z 1 Connect the carbon atom of formula (a) that was in position β to [ka]

[0107] Z 1 But, M A’ Another example of a compound where M A When is a self-immolative group of formula (b-1), Z 1 and M.A’ The second bond between 1 And Z 1 M is bound to A’ Connect the carbon atoms of M A’ The remaining bonds are delocalized. [ka]

[0108] In another aspect of the above embodiment, PZ 1 The bond breakage occurs in the compound HZ 3 -D and the formation of a conjugate base of a compound of the following formula: [ka]

[0109] In some embodiments of Formula (I) or Formula (II), Z 3 does not exist and M A is a self-immolative group. In some embodiments, the self-immolative group is PZ 1 The cleavage of the bond produces a cascade of decomposition reactions, ultimately resulting in the release of the conjugate base of the compound HO-(C=O)-D. In some aspects of these embodiments, PZ 1 The bond is broken by Z 1 =M A’ (as described herein) and results in the formation of a conjugate base of the compound HO-(O=C)-D.

[0110] In some embodiments of Formula (I) or Formula (II), Z 1 is S and M A is a self-immolative group of formula (a): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 The attachment points to the

[0111] In some embodiments of Formula (I) or Formula (II), the self-immolative group of formula (b) has the following formula (b-1): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 The attachment points to the

[0112] In some embodiments of Formula (I) or Formula (II), the self-immolative group of formula (b) has the following formula (b-2): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 The attachment points to the

[0113] In some embodiments of Formula (I) or Formula (II), the self-immolative group of formula (c) has the following formula (c-1): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 The attachment points to the

[0114] In some embodiments of Formula (I) or Formula (II), the self-immolative group of formula (d) has the following formula (d-1): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 The attachment points to the

[0115] In some embodiments of Formula (I) or Formula (II), Z 1 is O or NH, M A is a self-immolative group of any one of formulas (b)-(i). In some embodiments, Z 1 is O or NH, Z 3 does not exist and MA is a self-immolative group represented by any one of the formulae (b) to (i).

[0116] In some embodiments of Formula (I) or Formula (II), Z 1 is O or NH, Z 3 does not exist and M A is a self-immolative group of formula (b), where R 7 and R 8 are respectively, C 1-6 It is alkyl or has the formula (b-2).

[0117] In some embodiments of Formula (I) or Formula (II), Z 1 is O and Z 3 is NH or absent, and M A is a self-immolative group of formula (b), where R 7 and R 8 are each H or the formula (b-1).

[0118] In some embodiments of Formula (I) or Formula (II), Z 1 is O and Z 3 is O and M A is a self-immolative group of the following formula (h-1): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 The attachment points to the

[0119] In some embodiments of Formula (I) or Formula (II), Z 1 is O and Z 3 is O and M A is a self-immolative group of the following formula (i-1): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 The attachment points to the

[0120] In some embodiments of Formula (I) or Formula (II), Z 1 is NH and Z 3 is O and M A is a self-immolative group of formula (h-1). In some embodiments, Z 1 is NH and Z 3 is O and M A is a self-immolative group of formula (i-1).

[0121] In some embodiments of Formula (I), M A is a stable diradical. For example, a stable diradical is not a self-immolative group (e.g., upon nucleophilic attack on the phosphorus atom in formula (I), a stable diradical is Z 1 -M A Bond or M A -Z 3 (which does not result in bond cleavage). In some embodiments, the stable diradical is PZ 1 The bond breakage occurs according to the formula HZ 1 -M A -Z 3 -D, which is characterized by being stable and not subject to decomposition reactions.

[0122] In some embodiments, M A is a stable diradical having any one of the formulas (j) to (l), [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 In some aspects of these embodiments, Z 1 and Z 3 are independently O or NH (e.g., Z 1 is O and Z 3 In some embodiments, M A is a stable diradical of formula (j), Z 1 is O. In some embodiments, M Ais a stable diradical of formula (j), Z 1 is NH.

[0123] In some embodiments of Formula (I), M A is a stable diradical having the formula (m): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 In some aspects of these embodiments, Z 1 and Z 3 are independently O or NH (e.g., Z 1 is O and Z 3 In some embodiments, M A is a stable diradical of formula (m), Z 1 is O and R 7 and R 8 are each hydrogen.

[0124] In some embodiments of Formula (I) or Formula (II), R 7 and R 8 are independently H, C 1-6 Alkyl, amino, (C 1-6 Alkyl)amino, di-(C 1-6 In some embodiments, R is selected from the group consisting of alkyl, aryl ... 7 and R 8 is independently selected from H, methyl, amino, and acylamino. In some embodiments of Formula (I) or Formula (II), R 7 and R 8 are independently H and C 1-6In some embodiments, R 7 and R 8 is independently selected from H and methyl. In some embodiments, R 7 and R 8 are each hydrogen.

[0125] In some embodiments of Formula (I) or Formula (II), R 7 is C 1-6 Alkyl, C 3-7 R is selected from cycloalkyl, amino, acylamino, and a protected amino group, and R is H. In some embodiments, R 8 is C 1-6 Alkyl, C 3-7 R is selected from cycloalkyl, amino, acylamino, and protected amino groups; 7 is H.

[0126] In some embodiments of Formula (I) or Formula (II), R 8 is H and R 7 is C 1-6 In some embodiments, R is an alkyl group (e.g., methyl, ethyl, propyl, isopropyl, or tert-butyl). 7 is H and R 8 is C 1-6 In some embodiments, R is an alkyl group (e.g., methyl, ethyl, propyl, isopropyl, or tert-butyl). 7 and R 8 are both H. In some embodiments, R 7 and R 8 Both are C 1-6 In another example, R 7 and R 8 are both methyl. 7 is methyl, R 8 is ethyl. In some embodiments, R 7 and R 8 Both are C 3-7 It is cycloalkyl (eg, cyclopropyl or cyclobutyl).

[0127] In some embodiments of Formula (I) or Formula (II), R 7 and R 8 are each independently H or acylamino (e.g., acetylamino, propionylamino, or butylamino). In some embodiments, R 7 is amino or acetylamino. In some embodiments, R 8 is amino or acetylamino. In some embodiments, R 7 is acetylamino, and R 8 is H. In some embodiments, R 7 is H. In some embodiments, R 8 is H.

[0128] In some embodiments of Formula (I) or Formula (II), M A is a self-immolative group of any one of formulas (b), (c), or (d); R 7 and R 8 Both are C 1-6 In some embodiments, M is an alkyl group (e.g., methyl, ethyl, propyl, isopropyl, or tert-butyl). A is a stable diradical of formula (k) or formula (l), R 7 and R 8 is independently selected from H or acylamino (e.g., acetylamino, propionylamino, or butyramino).

[0129] In some embodiments of formula (I), the stable diradical of formula (k) has the following formula (k-1): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 The attachment points to the

[0130] In some embodiments of Formula (I) or Formula (II), R 1 and R 2 are independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 aryl, and optionally substituted 5-14 membered heteroaryl. In some embodiments, R 1 and R 2 Each is hydrogen. In some embodiments, R 1 and R 2 together form a chemical bond (i.e., a carbon-carbon double bond, R 1 and the carbon to which R is bonded 2 is formed between the carbon atom to which it is bonded).

[0131] In some embodiments of Formula (I) or Formula (II), R 1 and R 2 are joined together with the carbon atom to which they are attached to an optionally substituted C 3-7 Cycloalkyl rings, optionally substituted 4- to 7-membered aliphatic heterocyclic rings, optionally substituted C 6-10 aryl, or an optionally substituted 5-14 membered heteroaryl. In some embodiments, R 1 and R 2 Together, C 3-7 Forms a cycloalkyl ring (e.g., cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl). In some embodiments, R 1 and R 2 taken together form a 4- to 7-membered aliphatic heterocyclic ring (e.g., pyrrolidine, piperidine, tetrahydrofuran, and tetrahydropyran).

[0132] In some embodiments of Formula (I) or Formula (II), R 1 and R 2are linked together to form a ribose ring system (e.g., adenosine, guanosine, 5-methyluridine, uridine, 5-methylcytidine, cytidine, inosine, xanthosine, and wybutosine, each of which is substituted as described herein). In some embodiments, the ribonucleoside is uridine. In some embodiments, R 1 and R 2 together form a ribose ring system of the formula [ka] wherein either a represents the point of attachment to O and b represents the point of attachment to A, or a represents the point of attachment to A and b represents the point of attachment to O, and W is selected from the group consisting of H, an acyl group, a protecting group (e.g., a protecting group other than acyl). Without being bound by any theory, it is believed that lyxofuranose-based nucleotides have similar reactivity when compared to the ribofuranose analogs described herein.

[0133] Similarly, in one example, it is possible to hypothesize that the 5'-OH may participate in an intramolecular attack on the phosphotriester even though it is three carbons away. This is more demanding than the typical two-carbon distance interactions described herein, but this lyxo isomer may facilitate the reaction by reversing the orientation of the 3'OH. ​​Thus, 2'-deoxy, 3'-xylonucleosides are suitable alternatives to the ribonucleotide ribose scaffold described above for use in cleavable units.

[0134] In some embodiments of Formula (I) or Formula (II), the nucleobase is selected from the group consisting of adenine, cytosine, guanine, thymine, uracil, and other natural and unnatural nucleobases.

[0135] In some embodiments of Formula (I) or Formula (II), the nucleobase may be provided in its chemically protected form (eg, benzoyl or fatty acyl).

[0136] In some embodiments of formula (I) or formula (II), the nucleobase is uracil. In some embodiments, the nucleobase is selected from the group consisting of adenine, cytosine, guanine, thymine, and uracil. In some embodiments, the nucleobase is selected from the group consisting of 5-methylcytosine, pseudouridine, dihydrouridine, inosine, 7-methylguanosine, hypoxanthine, and xanthine.

[0137] In some embodiments of Formula (I) or Formula (II), the nucleobase comprises a fluorescent group (e.g., a traditional fluorophore). In some embodiments, the nucleobase is a fluorescent analog of adenine, cytosine, guanine, thymine, or uracil.

[0138] In some embodiments of Formula (I) or Formula (II), R 1 and R 2 together form a ribose ring system of any one of the following formulae: [ka] wherein either a represents a point of attachment to O and b represents a point of attachment to A, or a represents a point of attachment to A and b represents a point of attachment to O, and W is selected from the group consisting of H, an acyl group, and a protecting group (e.g., a protecting group other than acyl).

[0139] In some embodiments of Formula (I) or Formula (II), R 1 and R 2 together form a ribose ring system of any one of the following formulae: [ka] wherein either a represents a point of attachment to O and b represents a point of attachment to A, or a represents a point of attachment to A and b represents a point of attachment to O, and W is selected from the group consisting of H, an acyl group, and a protecting group (e.g., a protecting group other than acyl).

[0140] In some embodiments of Formula (I) or Formula (II), R1 and R 2 together form a ribose ring system of the formula [ka] wherein either a represents a point of attachment to O and b represents a point of attachment to A, or a represents a point of attachment to A and b represents a point of attachment to O, and W is selected from the group consisting of H, an acyl group, and a protecting group (e.g., a protecting group other than acyl). In some aspects of the above embodiments, the aliphatic moiety is selected from the group consisting of R P For example, R P is C 1-6 In another example, R P is cyanoethyl. In other aspects of the above embodiment, the aliphatic moiety is a polymer (e.g., polyethylene glycol). In other aspects of the above embodiment, the aliphatic moiety is a group represented by the formula: Polymer-L-(CH2) m -Based on

[0141] In some embodiments of Formula (I) or Formula (II), W is a protecting group. For example, W is a hydroxyl protecting group, such as a methoxymethyl ether (MOM), a benzyloxymethyl ether (BOM), a benzyl ether, a p-methoxybenzyl ether (PMB), a trityl ether, a silyl ether (e.g., TMS, TIPS), or a hydroxyl protecting group, such as ... thEd., Wiley & Sons, Inc., New York (2006), which is incorporated herein by reference in its entirety. In some embodiments, W is an alcohol protecting group selected from the group consisting of t-butyldimethylsilyl, diethylisopropylsilyl, triphenylsilyl, formate, methoxymethylcarbonate, t-butylcarbonate, 9-fluorenylmethylcarbonate, N-phenylcarbamate, 4,4'-dimethoxytrityl, monomethoxytrityl, trityl, and pixyl.

[0142] In some embodiments, W is hydrogen.

[0143] In some embodiments, W is an acyl group.

[0144] In some embodiments of Formula (I) or Formula (II), W is any one of the acyl groups described herein (e.g., W is an acyl group selected from formyl, acetyl, propionyl, acrylyl, pivaloyl, and benzoyl). In some embodiments, W is pivaloyl or benzoyl. In some embodiments, W and E are the same (e.g., W and E are each acyl groups). In some embodiments, W is an acyl group and E is a cleavable group other than an acyl group. In some embodiments, the acyl group is hydrolyzable in the presence of any one of a number of hydrolases present in vivo.

[0145] In some embodiments of Formula (I) or Formula (II), A is selected from the group consisting of O and N(R N In some embodiments, A is selected from O. In some embodiments, A is selected from N(R N In some embodiments, A is NH. In some embodiments, A is N(C 1-6 In some embodiments, A is N(CH3). In some embodiments, A is N(CH2CH3).

[0146] In some embodiments, A is N(R N ), then R N and R 1 A and R 1 together with the carbon atom to which it is attached to form an optionally substituted 4-7 membered aliphatic heterocyclic ring. In some aspects of these embodiments, the 4-7 membered aliphatic heterocyclic ring is selected from the group consisting of: [ka] where x indicates the point of attachment to E and y indicates R 1 indicates the point of attachment to the carbon atom to which it is bonded.

[0147] In some embodiments, R N and R 2 A, R 1 The carbon atom to which is bonded, and R 2 together with the carbon atom to which it is attached form an optionally substituted 4- to 8-membered aliphatic heterocyclic ring.

[0148] In some embodiments, when A contains N, the moiety: [ka] A 2-aminoalcohol that is not serine or a derivative thereof, threonine or a derivative thereof, or cis-aminoindanol or a derivative thereof. In some embodiments, the 2-aminoalcohol is not aminoethanol.

[0149] In some embodiments, the compound of formula (II) has the formula (II-1a): [ka] or a pharma- ceutically acceptable salt thereof.

[0150] In some embodiments, the compound of formula (II) has the formula (II-1b): [ka] or a pharma- ceutically acceptable salt thereof.

[0151] In some embodiments, the compound of formula (II) has the formula (II-1c): [ka] or a pharma- ceutically acceptable salt thereof.

[0152] In some embodiments, the compound of formula (II) has the formula (II-2a): [ka] or a pharma- ceutically acceptable salt thereof.

[0153] In some embodiments, the compound of formula (II) has the formula (II-2b): [ka] or a pharma- ceutically acceptable salt thereof.

[0154] In some embodiments, the compound of formula (II) has the formula (II-3a): [ka] or a pharma- ceutically acceptable salt thereof.

[0155] In some embodiments, the compound of formula (II) has the formula (II-3b): [ka] or a pharma- ceutically acceptable salt thereof.

[0156] In some embodiments, the compound of formula (II) has the formula (II-4a): [ka] or a pharma- ceutically acceptable salt thereof.

[0157] In some embodiments, the compound of formula (II) has the formula (II-4b): [ka] or a pharma- ceutically acceptable salt thereof.

[0158] In some embodiments, the compound of formula (II) has any one of the following formulae (II-5) to (II-7): [ka] In the formula (II-7), A is O. or a pharma- ceutically acceptable salt thereof.

[0159] In some embodiments, the compound of formula (II) has the formula (II-8): [ka] or a pharma- ceutically acceptable salt thereof.

[0160] In some embodiments, the compound of formula (II) has the formula (II-9): [ka] or a pharma- ceutically acceptable salt thereof.

[0161] In some embodiments, the compound of formula (II) has the formula (II-10): [ka] or a pharma- ceutically acceptable salt thereof.

[0162] In some embodiments, the compound of formula (II) has the formula (II-10a): [ka] or a pharma- ceutically acceptable salt thereof.

[0163] In some embodiments, the compound of formula (II) has the formula (II-11a): [ka] or a pharma- ceutically acceptable salt thereof.

[0164] In some embodiments, the compound of formula (II) has the formula (II-11): [ka] or a pharma- ceutically acceptable salt thereof.

[0165] In some embodiments, the compound of formula (II) has the formula (II-12a): [ka] or a pharma- ceutically acceptable salt thereof.

[0166] In some embodiments, the compound of Formula (II) has the formula (II-12b): [ka] or a pharma- ceutically acceptable salt thereof.

[0167] In some embodiments, the compound of formula (II) has the formula (II-13): [ka] or a pharma- ceutically acceptable salt thereof.

[0168] In some embodiments, the compound of formula (II) has the formula (II-14): [ka] or a pharma- ceutically acceptable salt thereof.

[0169] In some embodiments, the compound of formula (II) has the formula (II-15): [ka] or a pharma- ceutically acceptable salt thereof.

[0170] In some embodiments, the compound of formula (II) has the formula (II-16): [ka] or a pharma- ceutically acceptable salt thereof. In some aspects of these embodiments, R P is an arbitrarily substituted C 1-6 It is alkyl (eg, isopropyl or cyanoethyl).

[0171] In some embodiments, the compound of formula (II) has the formula (II-17): [ka] or a pharma- ceutically acceptable salt thereof.

[0172] In some embodiments, the compound of formula (II) has the formula (II-18): [ka] or a pharma- ceutically acceptable salt thereof.

[0173] In some embodiments, R N is H. In some embodiments, R N is C 1-6Alkyl (eg, methyl, ethyl, propyl, isopropyl).

[0174] In some embodiments, the compound of formula (II) has the formula (II-19a): [ka] or a pharma- ceutically acceptable salt thereof.

[0175] In some embodiments, the compound of Formula (I) or Formula (II) is a compound that is not: [ka] or a pharma- ceutically acceptable salt thereof, wherein U is uracil.

[0176] Cleavable E group In some embodiments of Formula (I) or Formula (II), E is a cleavable moiety that upon cleavage liberates a free AH group, where H is hydrogen. The cleavable moiety E can be, for example: 1) an E moiety cleavable by any one of the following enzymes:

[0177] a) Esterase All esters, carbonates, and methyloxyesters can be hydrolyzed by esterase enzymes. The reactivity of these functional groups in the enzymatic reaction can be adjusted by choosing the carboxylic acid component of the ester functional group to contain different electron donating groups or by creating sterically hindered esters. Both the acid and alcohol components of the ester can be sterically hindered.

[0178] b) reductase Methyl-dithioether, methyl azide group, and 2-oxymethylene anthraquinone carbonate (MAQC) are examples of cleavable moieties E that can both be cleaved by a reductase enzyme. For example, the reductase-cleavable moiety E can be a methyl azide group or the moiety E can be of the formula: [ka]

[0179] c) glycosidase When AE represents a heteroatom substituted with a sugar residue that forms a glycosidic bond with the remainder of the compound of formula (I) or formula (II), the action of a glycosidase in vivo can cleave E and liberate free AH.

[0180] 2) A moiety E that is cleavable by base but at physiological pH via a β-elimination mechanism (e.g., a β-elimination trigger).

[0181] a) For example, moiety E can be a fluorenylmethylcarbamide-type trigger having the formula: [ka] In the formula, R is H, C 1-10 The radicals are selected from alkyl, OH, NO2, CN, halogen, and acetyl. The introduction of an electron-withdrawing substituent R can increase the rate of beta-elimination and release of the free AH. In another example, the moiety E below bears an electron-withdrawing -SO2- group. [ka]

[0182] b) Substituted β-phenylsulfonylethyl carbamates and carbonates: [ka] In the formula, R is H, C 1-10The functional groups are selected from alkyl, OH, NO2, CN, halogen, and acetyl. These functional groups are cleaved via a β-elimination mechanism at about pH 7.4, and the rate of this process can be controlled by the substituent R on the phenyl ring.

[0183] In some embodiments, E is cleavable by an enzyme selected from the group consisting of esterases, specific or non-specific peptidases, reductases, oxidases, glycosidases, hydrolases, glycosyltransferases, and transaminases. In some embodiments, E is cleavable by an enzyme selected from the group consisting of esterases, reductases, oxidases, glycosides, hydrolases, and glycosyltransferases.

[0184] 3) Acid-cleavable moieties. Any acid-cleavable alcohol protecting group can be used as the cleavable moiety E. For example, acetals, ortho-esters, and phenyl-substituted ethers can be used. Examples of such cleavable moieties include protecting groups such as THF, MTHP, or MDMP, and more labile acetals such as methoxyisopropyl acetal or methoxycyclohexenyl acetal. Other examples of this type of cleavable moiety E that are cleaved in an acidic environment include dimethoxytrityl, trimethoxytrityl, and pixyl groups.

[0185] In some embodiments, E contains a dithio group that is cleavable by a biological thiol. In some embodiments of Formula (I) or Formula (II), the moiety E is cleavable by glutathione.

[0186] In some embodiments, E is a group of any one of the following formulae: [ka] In the formula, R E But, C 1-6In some embodiments, R is selected from the group consisting of alkyl and benzyl. E is C 1-6 In some embodiments, R E is benzyl.

[0187] In some embodiments, A is O and E is a group of the formula: [ka]

[0188] In some aspects of these embodiments, A is NH and E is a group of the formula: [ka]

[0189] In some embodiments of formula (I) or formula (II), E is cleavable by an enzyme selected from the group consisting of esterases, reductases, oxidases, and glycosidases or glycosyltransferases. In other embodiments, E is non-enzymatically cleavable at acidic or physiological pH. In some embodiments, E is an acyl group, an O-methyl-acyl group, a methyl azide group, a sugar residue, a protected acetal, or a carbonate ester. In some of these embodiments, A is O. In other embodiments, A is NH.

[0190] In some embodiments of Formula (I) or Formula (II), the acyl group is formyl, acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, cyanoacetyl, mono-methylmalonate, mono-ethylmalonate, methoxyacetyl, ethoxyacetyl, t-butoxyacetyl, phenoxyacetyl, t-butylphenoxyacetyl, glycolate, acetyl glycolate, propionate, 2-chloropropionate, 3-chloropropionate, 2-cyanopropionate, 3-cyanopropionate, N-acetyl-glycinate, N-trifluoroacetylglycinate, N-acetylalanilate, N-trifluoroacetylalanilate, N-acetylphenylalanilate, N-trifluoroacetylphenylalanilate, N-acetylvalinate, N-trifluoroacetylvalinate, N- ... E is selected from the group consisting of linyl-citrunyllate, N-trifluoroacetylvalinyl-citrunylate, butyrate, isobutyrate, pivaloate, levulinate, monomethyl oxalate, mono-ethyl oxalate, mono-methyl succinate, mono-ethyl succinate, hydroxyl butyrate, acetoxybutyrate, acetylbutyrate, hexanoate, palmitate, stearate, benzoate, chloro-benzoate, dichloro-benzoate, pentachlorobenzoate, cyano-benzoate, aminobenzoate, acetamino-benzoate, mono-methyl-phthalate, mono-ethyl-phthalate, methoxy-benzoate, trimethoxybenzoate, trifluoromethylbenzoate, dimethylaminobenzoate, and methylsulfonylbenzoate. In some embodiments, E is an acyl group selected from formyl, acetyl, propionyl, acrylyl, pivaloyl, and benzoyl.

[0191] In some embodiments of Formula (I) or Formula (II), E is cleavable by an esterase enzyme, e.g., E is an acyl group (e.g., any of the acyl groups described herein), a carbonate ester, or an O-methyl-acyl ester.

[0192] In some embodiments of Formula (I) or Formula (II), E is cleavable by a reductase.

[0193] In some aspects of these embodiments, A is O and E is a group of the formula: [ka]

[0194] In some aspects of these embodiments, A is NH and E is a group of the formula: [ka]

[0195] In some embodiments of Formula (I) or Formula (II), E is cleavable by glutathione. In some aspects of these embodiments, A is NH. In other aspects of these embodiments, E is a moiety of the formula: [ka]

[0196] In some embodiments of Formula (I) or Formula (II), E is cleavable by a glycosidase. In some aspects of these embodiments, E is a residue of a sugar (e.g., glucose, galactose, or mannose).

[0197] In some embodiments of Formula (I) or Formula (II), E is cleavable at physiological pH via a beta-elimination mechanism. For example, E is selected from the group of any one of the following formulae: [ka] In the formula, R is H, C 1-10In another example of a moiety cleavable at physiological pH, E is an acyl group (e.g., any one of the acyl groups described herein, such as pivaloyl or benzoyl).

[0198] Another example of a moiety cleavable at physiological pH via a β-elimination mechanism is A, NR N or NR 3 and E is a cleavable moiety of the formula: [ka] During the ceremony, R 9 H, optionally substituted C 6-10 Aryl and optionally substituted C 1-6 alkyl, R 10 and R 11 are independently H, CN, NO2, and COR 12 , SOR 12 or SO2R 12 , optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 aryl, and optionally substituted 5- to 14-membered heteroaryl; R 10 and R 11 together with the carbon atom to which they are attached, one or more optionally substituted C 6-10 Optionally substituted C fused to an aryl ring 3-7 forming a cycloalkyl ring, R 12 But, with any substitution C 1-6 Alkyl and optionally substituted C 6-10 aryl, and in some aspects of these embodiments, A is NH and R 9 is H and optionally substituted C 6-10 aryl.

[0199] In some embodiments of Formula (I) or Formula (II), E is a cleavable moiety of any one of the following formulae (E-1)-(E-12), (E-37), and (E-39)-(E-41): [ka] In the formulae, any one of the phenyl rings of the formulae (E-1) to (E-12), (E-37) and (E-39) to (E-41) is C 1-10 Alkyl, C 1-10 Haloalkyl, C 1-10 Optionally substituted with 1, 2, 3, 4, or 5 substituents selected from alkoxy, OH, NO2, CN, halogen, and acyl. In some aspects of these embodiments, E is a cleavable moiety of any one of formulae (E-1)-(E-12). In some embodiments, the substituents on the phenyl ring of formulae (E-1)-(E-12), (E-37), and (E-39)-(E-41) modify the stability and lability of the cleavable group. In one example, the cleavable moiety E can be of the fluorenylmethylcarbamide type having the formula: [ka]

[0200] In one example, the cleavable moiety E can be of the fluorenylmethylcarbamide type having the following formula: [ka]

[0201] For example, the introduction of an electron-withdrawing substituent R, such as cyano, halogen, nitro, sulfonyl, or acyl, can increase the rate of β-elimination and release of the free AH. In contrast, e.g., C 1-6 Introduction of an electron donating substituent R, such as alkyl or silyl, can stabilize the moiety E against β-elimination.

[0202] Substituted β-phenylsulfonylethyl carbamates and carbonates, such as (4-X-phenyl)sulfonylethoxycarbonyl (PSEC or XPSEC) groups, are examples of these useful moieties. [ka] In the formula, the substituent X is H, C 1-10 Alkyl, C 1-10 Haloalkyl, C 1-10 In some embodiments, X is selected from the group consisting of alkoxy, OH, NO2, CN, halogen, and acyl. In some embodiments, X is selected from H, Cl, and methoxy.

[0203] In some embodiments, the PSEC group is a group of the formula: [ka]

[0204] In some embodiments of Formula (I) or Formula (II), any one of the phenyl rings of Formulas (E-1) through (E-12), (E-37), or (E-39) through (E-41) is optionally substituted with 1, 2, 3, or 10 substituents selected from F, Cl, CN, acetyl, NO2, and CF3. For example, (E-1) can be substituted with F to provide Formula (E-42). [ka]

[0205] In some embodiments of Formula (I) and Formula (II), E is not (E-38).

[0206] In some embodiments of formula (I) or formula (II), E is cleavable at acidic pH. For example, E is a moiety selected from acetal, ortho-ester, and substituted triphenylmethyl ether. In further examples of moieties E that are cleavable at acidic pH, E may be selected from tetrahydrofuranyl, 4-methoxytetrahydropyran-4-yl, 1,5-dicarbo-methoxypentanyl, methoxyisopropylacetal, methoxycyclohexenylacetal, dimethoxytrityl, trimethoxytrityl, and pixyl.

[0207] In some embodiments of formula (I) or formula (II), the moiety E is cleavable by base at physiological pH via a beta-elimination mechanism or in an autocatalytic manner beginning with deprotonation of the most basic amino group of the E group. In one example, such an E moiety is an oligoamide (e.g., a diamide or triamide). In some aspects of these embodiments, A is nitrogen (e.g., A is NH). For example, E is any one of the oligoamides described in U.S. Patent Publication No. US2015 / 0057221, U.S. Patent Publication No. US2014 / 0249093, U.S. Patent No. 8,377,917, U.S. Patent No. 8,906,847, U.S. Patent No. 9,173,953, or U.S. Patent No. 9,062,094, all of which are incorporated herein by reference. In one embodiment, E is a cleavable moiety selected from any one of the following formulae (E-13)-(E-36): [ka] JPEG0007675648000116.jpg143166 where R is as described herein.

[0208] In some embodiments of Formula (I) or Formula (II), the moiety E that is cleavable at physiological pH, e.g., via a β-elimination mechanism, is any one of the β-elimination moieties described in, e.g., U.S. Pat. No. 9,387,245 or U.S. Pat. No. 8,754,190, both of which are incorporated herein by reference.

[0209] In some embodiments of formula (I) or formula (II), the moiety E has the following formula: E ) group is attached to A, [ka] wherein a indicates the point of attachment to A and b indicates the point of attachment to E. In some aspects of these embodiments, A is O. In other aspects of these embodiments, upon cleavage of moiety E, a group of formula L E The group undergoes a decomposition reaction to give CO2 and a compound of the formula: [ka] Therefore, free A - A group is released that can undergo nucleophilic attack on the phosphorus atom of the compound of formula (I) or formula (II). - The group may also be protonated to give the group AH prior to nucleophilic attack.

[0210] In one example, in the compound of formula (II-8a), the chloro-PSEC cleavable moiety E is of formula L E When the chloro-PSEC moiety in compound (II-8a) is non-enzymatically cleaved via a β-elimination mechanism, the resulting moiety L E The decomposition of can occur, for example, as shown in Scheme 3. Scheme 3 [ka]

[0211] In some embodiments, any one of the cleavable moieties (E-1) through (E-36) is represented by the formula (L E ) moiety can be used to attach to A.

[0212] In some embodiments, the E moiety may be cleaved through enzyme catalysis through a β-elimination mechanism at physiological pH or hydrolyzed at acidic pH. For example, when a compound of formula (I) or formula (II) is subjected to enzyme conditions at physiological pH, the E group in the compound may be cleaved by enzymes or by β-elimination, or both, depending on which reaction is kinetically favored under the given conditions. In another example, when a compound of formula (I) or formula (II) is subjected to enzyme conditions at acidic pH, the E group in the compound may be cleaved by enzymes or by hydrolysis, or both, depending on the difference in activation energy between the enzyme hydrolysis reaction and the acid hydrolysis reaction.

[0213] GLP-1 Polypeptides or Analogues Thereof In some embodiments of Formula (I) or Formula (II), D comprises a residue of any one of the glucagon-like peptide 1 (GLP-1) polypeptides or analogs thereof described herein. The residue of the GLP-1 polypeptide or analog thereof in Formula (I) or Formula (II) may be designated as "D" or "drug", and these symbols are used interchangeably herein.

[0214] In some embodiments of Formula (I) or Formula (II), HZ 3 - may represent the amino or hydroxyl group of the side chain of an amino acid (e.g., lysine) in the polypeptide backbone, and D represents the remainder of the polypeptide backbone. For example, HZ 3 - can be the ε-amino group of lysine. 3 - may be the OH- group of serine.

[0215] In some embodiments of Formula (I) or Formula (II), HZ 3 - may represent a terminal amino or hydroxyl group of the polypeptide backbone (e.g., the terminal amine of histidine), and D represents the remainder of the polypeptide backbone. For example, HZ 3- can be the N-terminal amine group of the N-terminal amino acid (e.g., histidine). 3 - may be the OH- group of the C-terminal carboxylic acid of the terminal amino acid of the polypeptide.

[0216] In some embodiments of the compounds of Formula (I) or Formula (II), Z 3 is not present, the GLP-1 polypeptide or analog thereof may be described as a compound of formula H2N-D prior to conjugation to form a compound of formula (I) or formula (II). In this example, the self-immolative group M of any one of formulas (a)-(g) is A The following part of the formula in [ka] represents the portion of the drug after it has been conjugated to form a compound of formula (I) or formula (II), in which x is the self-immolative group M A’ (as described herein) or to H of the drug H2N-D prior to conjugation, and y represents the point of attachment to D.

[0217] In some embodiments of the compounds of Formula (I) or Formula (II), Z 3 is not present, the GLP-1 polypeptide or analogue thereof may be described as a compound of formula H2N-D prior to conjugation to form a compound of formula (I) or formula (II). In this case, when the GLP-1 polypeptide or analogue thereof has the formula H2N-D, the moiety H2N- represents the terminal amine group of the GLP-1 polypeptide or analogue thereof, and D comprises a residue of the GLP-1 polypeptide or analogue thereof.

[0218] In one example, prior to being conjugated to form a compound of formula (I) or formula (II) described herein, the GLP-1 polypeptide or analog thereof may be represented by the formula HZ 3 D compound, HZ 3 - represents a reactive amino or hydroxyl group of the GLP-1 polypeptide or analog thereof (Z3 is nitrogen or oxygen, respectively), D comprises a residue of a GLP-1 polypeptide or an analog thereof. In one example, prior to being conjugated to form a compound of formula (I) or formula (II) described herein, the GLP-1 polypeptide or an analog thereof is represented by the formula HZ 3 D compound, HZ 3 - represents a reactive amino or hydroxyl group of the GLP-1 polypeptide or analog thereof (Z 3 is nitrogen or oxygen, respectively), and D is a residue of a GLP-1 polypeptide or an analog thereof.

[0219] Non-limiting examples of GLP-1 polypeptides or analogs thereof include: GLP-1(1-37): HDEFERHAEGTFTSDV SSYLEGQAAK EFIAWLVKGR G (SEQ ID NO: 1) GLP-1(7-37): HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR G (SEQ ID NO: 2) Here, this sequence corresponds to amino acids 7-37 of the GLP-1(1-37) polypeptide sequence.

[0220] Liraglutide (VICTOZA®, K26 liraglutide) is a GLP-1 polypeptide analogue with a C16 fatty acid chain (palmitic acid) via a glutamyl spacer from a lysine residue and is represented as follows: HAEGTFTSDV SSYLEGQAAK (γ-Glu-palmitoyl) EFIAWLVRGR G (SEQ ID NO: 3) Here, this sequence is an analog of amino acids 7-37 of the GLP-1(1-37) polypeptide sequence.

[0221] Liraglutide Fragment 1: HAEGTFTSDV SSYLEGQAAK EFIAWLVRGR G (SEQ ID NO: 4) Liraglutide Fragment 2: EGTFTSDV SSYLEGQAAK EFIAWLVRGR G (SEQ ID NO: 5) Liraglutide Fragment 3: TSDV SSYLEGQAAK EFIAWLVRGR G (SEQ ID NO: 6) Liraglutide Fragment 4: AK EFIAWLVRGRG (SEQ ID NO: 7)

[0222] Dulaglutide (LY2189265, TRULICITY®) is a molecule consisting of two identical disulfide-linked chains, each containing an analog sequence of human GLP-1 covalently linked to a modified human immunoglobulin G4 (IgG4) heavy chain fragment (Fc) by a small peptide linker.

[0223] The GLP-1 analog sequence is represented as follows: HGEGTFTSDV SSYLEEQAAK EFIAWLVKGG G (SEQ ID NO: 8)

[0224] The immunoglobulin sequences are represented as follows: ESK YGPPCPPCPA PEAAGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLG (SEQ ID NO: 9)

[0225] The small peptide linker is represented as follows: GGGGSGGGG SGGGGSA (SEQ ID NO: 10)

[0226] The full-length sequence of one monomer of dulaglutide (LY2189265, TRULICITY®) is represented as follows: HGEGTFTSDV SSYLEEQAAK EFIAWLVKGG GGGGGSGGGG SGGGGSAESK YGPPCPPCPA PEAAGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLG (SEQ ID NO: 11)* *Disulfide bridge position: 55-55′ 58-58′ 90-150 90′-150′ 196-254 196′-254′

[0227] Exenatide (BYETTA®, BYDUREON, Exendin-4) and Exenatide LAR (GLP-1 moiety is the same). HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS (SEQ ID NO: 12)

[0228] Taspoglutide HXEGTFTSDV SSYLEGQAAK EFIAWLVKXR (SEQ ID NO: 13) where X is 2-methylalanine.

[0229] Lixisenatide (LYXUMIA®) HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPSKK KKKK (SEQ ID NO: 14) where T is threonine and I is isoleucine.

[0230] Albiglutide (TANZEUM®) is a polypeptide of 645 proteinogenic amino acids with 17 disulfide bridges. Amino acids 1-30 and 31-60 constitute two copies of modified human GLP-1.

[0231] The GLP1 fragment is represented by: HGEGTFTSDV SSYLEGQAAK EFIAWLVKGR (SEQ ID NO: 15)

[0232] The full length sequence of albiglutide is represented as follows: HGEGTFTSDV SSYLEGQAAK EFIAWLVKGR HGEGTFTSDV SSYLEGQAAK EFIAWLVKGR DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV KLVNEVTEFA KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGEMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY EIARRHPYFY APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK VHTECCHGDL LECADDRADL AKYICENQDS ISSKLKECCE KPLLEKSHCI AEVENDEMPA DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPD YSVVLLLRLA KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH PEAKRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD FAAFVEKCCK ADDKETCFAE EGKKLVAASQ AALGL (SEQ ID NO: 16)

[0233] Semaglutide (OZEMPIC®) H-Aib-EGTFTSDV SSYLEGQAAK (AEEAc-AEAc-γ-Glu-17-carboxyheptadecanoyl) EFIAWLVRGR G (SEQ ID NO: 17) Here, Aib is α-aminoisobutyric acid.

[0234] A diagram of the selection of GLP-1 analogs is provided in Figure 8. See also Dods, RL and Donnelly, D. Bioscience Reports 36(1)e2085 (Jan. 15, 2016), and Li, Y et al. Reviews in Neurosciences 27(7):689-711 (2016).

[0235] In some embodiments, glucagon-like peptide 2 (GLP-2) or an analog thereof can be used in place of the GLP-1 polypeptides and analogs thereof described herein. Non-limiting examples of GLP-2 polypeptides and analogs thereof include: GLP-2 HADGSFSDEM NTILDNLAAR DFINWLIQTK ITD (SEQ ID NO: 18)

[0236] Teduglutide (GATTEX®) HGDGSFSDEM NTILDNLAAR DFINWLIQTK ITD (SEQ ID NO: 19)

[0237] FE203799 HGDGSFSDENle[d-Phe]TILDLLAARDFINWLIQTKITD (SEQ ID NO: 20) Grepaglutide (ZP1848) HGEGTFSSEL ATILDALAAR DFIAWLIATK ITD-KKKKKK (SEQ ID NO: 21)

[0238] Elsiglutide (ZP1846) HGEGSFSSELSTILDALAARDFIAWLIATKITDKKKKK (SEQ ID NO: 22)

[0239] Any of the above sequences may be present in a polypeptide having at least 80% sequence identity to any of the above sequences.For example, the compounds provided herein may include a polypeptide having at least 80%, at least 85%, at least 88%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to the listed sequences.For example, D includes a residue of a GLP-1 polypeptide or an analog thereof, and the GLP-1 polypeptide or an analog thereof has at least 80% sequence identity (e.g., at least 85%, at least 88%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) to the GLP-1 polypeptide or an analog thereof provided herein.

[0240] In some embodiments, the polypeptide is 30 to 100 amino acids long. For example, 31 to 100 amino acids long, 35 to 100 amino acids long, 40 to 100 amino acids long, 50 to 100 amino acids long, 60 to 100 amino acids long, 70 to 100 amino acids long, 80 to 100 amino acids long, 90 to 100 amino acids long, 30 to 90 amino acids long, 30 to 80 amino acids long, 30 to 70 amino acids long, 30 to 60 amino acids long, 30 to 50 amino acids long, 30 to 40 amino acids long, 40 to 60 amino acids long, 50 to 70 amino acids long, 31 to 41 amino acids long, or 31 to 50 amino acids long. In some embodiments, the polypeptide is less than 50 amino acids long. For example, less than 45 amino acids long, less than 40 amino acids long, or less than 35 amino acids long. In some embodiments, the polypeptide is 30 to 300 amino acids long. For example, 31-300 amino acids in length, 50-300 amino acids in length, 80-300 amino acids in length, 90-300 amino acids in length, 100-300 amino acids in length, 150-300 amino acids in length, or 200-300 amino acids in length.

[0241] The percent sequence identity between a particular nucleic acid or amino acid sequence and a sequence referenced by a particular sequence identification number is determined as follows. First, the nucleic acid or amino acid sequence is compared to the sequence set forth in the particular sequence identification number using the BLAST2 sequence (B12seq) program from the standalone version of BLASTZ, which contains BLASTN version 2.0.14 and BLASTP version 2.0.14. This standalone version of BLASTZ is available online at fr.com / blast or ncbi.nlm.nih.gov. Instructions on how to use the B12seq program can be found in the readme file that accompanies BLASTZ. B12seq uses either the BLASTN or BLASTP algorithm to perform a comparison between two sequences. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. To compare two nucleic acid sequences, the following options are set: -i is set to a file containing the first nucleic acid sequence to be compared (e.g., C:\seql.txt), -j is set to a file containing the second nucleic acid sequence to be compared (e.g., C:\seq2.txt), -p is set to blastn, -o is set to any desired file name (e.g., C:\output.txt), -q is set to -1, -r is set to 2, and all other options are left at their default settings. For example, the following command can be used to generate an output file containing a comparison between two sequences: C:\B12seq-i c:\seql.txt-j c:\seq2.txt-p blastn-o c:\output.txt-q-1-r 2. To compare two amino acid sequences, the B12 sequence options are set as follows:-i is set to a file containing the first amino acid sequence to be compared (e.g., C:\seql.txt), -j is set to a file containing the second amino acid sequence to be compared (e.g., C:\seq2.txt), -p is set to blastp, -o is set to any desired file name (e.g., C:\output.txt), and all other options are left at their default settings. For example, the following command can be used to generate an output file containing a comparison between two amino acid sequences: C:\B12seq-i c:\seql.txt-j c:\seq2.txt-p blastp-o c:\output.txt. If the two compared sequences share homology, the specified output file will present these regions of homology as an aligned sequence. If the two compared sequences do not share homology, the specified output file will not present an aligned sequence.

[0242] Upon alignment, the number of matches is determined by counting the number of positions where identical nucleotides or amino acid residues are present in both sequences. The percent sequence identity is determined by dividing the number of matches by either the length of the sequence shown in the identified sequence (e.g., SEQ ID NO:1) or the spanned length (e.g., 100 consecutive nucleotides or amino acid residues from the sequence shown in the identified sequence), and then multiplying the resulting value by 100. For example, an amino acid sequence with 25 matches when aligned with the sequence shown in SEQ ID NO:1 is 95.6% identical to the sequence shown in SEQ ID NO:1 (i.e., 25 / 31×100=80.6). Note that the percent sequence identity values ​​are rounded to the nearest tenth. For example, 75.11, 75.12, 75.13, and 75.14 are rounded down to 75.1, and 75.15, 75.16, 7.17, 75.18, and 7.19 are rounded up to 7.2. Also, note that the length value is always an integer.

[0243] Analogs provided herein include, for example, polypeptide variants having one or more amino acid substitutions, deletions, or insertions. In some embodiments, variants have at least one amino acid substitution, deletion, or insertion. In some embodiments, variants have at least two amino acid substitutions, deletions, or insertions. In some embodiments, variants have at least three amino acid substitutions, deletions, or insertions. Analogs provided herein include fragments. As used herein, a "fragment" as applied to a polypeptide is usually at least 10 residues in length, more typically at least 20 residues, preferably at least 30 residues (e.g., 50 residues), but less than the full length of the intact sequence. Analogs (e.g., variants and fragments) can be produced by methods known to those of skill in the art, for example, by enzymatic digestion of natural or recombinant proteins, by recombinant DNA technology using expression vectors encoding defined fragments, or by chemical synthesis.

[0244] In some embodiments, the GLP-1 polypeptides or analogs thereof, including those of SEQ ID NO:1-SEQ ID NO:22, are biologically inactive or only weakly biologically active when conjugated to an aliphatic moiety (e.g., PEG) such as those of formula (I) or formula (II) as compared to the free, unconjugated form of the polypeptide. The polypeptides can regain their biological activity after being released from the aliphatic moiety (e.g., PEG moiety) of the compound of formula (I) or formula (II). For example, the compounds of formula (I) or formula (II) have the ability to function as prodrugs in mammals (e.g., humans) and remain inactive compared to the unconjugated GLP-1 polypeptides or analogs thereof until the GLP-1 polypeptides or analogs thereof are released from the aliphatic moiety (e.g., PEG moiety) of formula (I) or formula (II). In some cases, as shown in FIG. 9, compound 7 (in which the polypeptide liraglutide is conjugated to a PEG moiety) remains inactive compared to unconjugated liraglutide until liraglutide is released from the aliphatic moiety (e.g., the PEG moiety) of compound 7 (see results and discussion in Example 11).

[0245] polymer In some embodiments, the aliphatic moiety can be a polymer. As described herein, the polymer can be branched or linear. For example, the polymer can have 2-100 ends (e.g., 2-80, 2-75, 2-60, 2-50, 2-40, 2-35, 2-25, 2-10, 2-5, 4-20, 5-25, 10-50, 25-75, 3-6, 5-15 ends). In some embodiments, the polymer can have 2-5, 4-6, 5-6, or 3-6 ends. In some embodiments, the polymer is linear and thus has two ends. In some embodiments, one end of the polymer is covalently bonded to a structure of any one of the formulas provided herein.

[0246] The polymer can be, for example, a poly(alkylene glycol), a poly(oxyethylated polyol), a poly(olefinic alcohol), a poly(β-hydroxy acid), a poly(vinyl alcohol), a polyoxazoline, or a copolymer thereof. Polyalkylene glycols include linear or branched polymeric polyether polyols. Such polyalkylene glycols include, but are not limited to, polyethylene glycol (PEG), polypropylene glycol, polybutylene glycol, and derivatives thereof. Other exemplary embodiments are described in commercial supplier catalogs, such as, for example, Shearwater Corporation's catalog "Polyethylene Glycols and Derivatives for Biomedical Applications" (2001).

[0247] In some embodiments, such polymeric polyether polyols have an average molecular weight of about 0.1 kDa to about 100 kDa. For example, such polymeric polyether polyols include, but are not limited to, about 500 Da to about 100,000 Da or more. The molecular weight of the polymer may be about 500 Da to about 100,000 Da. For example, the polymers used herein may be about 100,000 Da, 95,000 Da, 90,000 Da, 85,000 Da, 80,000 Da, 75,000 Da, 70,000 Da, 65,000 Da, 60,000 Da, 55,000 Da, 50,000 Da, 45,000 Da, 40,000 Da, 35,000 Da, 30,000 Da, 40,000 Da, 50,000 Da, 55,000 Da, 60,000 Da, 75,000 Da, 80,000 Da, 80,000 Da, 90,000 Da, 10 ... The molecular weight of the polymer may be 0 Da, 25,000 Da, 20,000 Da, 15,000 Da, 10,000 Da, 9,000 Da, 8,000 Da, 7,000 Da, 6,000 Da, 5,000 Da, 4,000 Da, 3,000 Da, 2,000 Da, 1,000 Da, 900 Da, 800 Da, 700 Da, 600 Da, and 500 Da. In some embodiments, the molecular weight of the polymer is about 500 Da to about 50,000 Da. In some embodiments, the molecular weight of the polymer is about 500 Da to about 40,000 Da. In some embodiments, the molecular weight of the polymer is about 1,000 Da to about 40,000 Da. In some embodiments, the molecular weight of the polymer is from about 5,000 Da to about 40,000 Da. In some embodiments, the molecular weight of the polymer is from about 10,000 Da to about 40,000 Da.

[0248] In some embodiments, the polymer is a linear or branched poly(ethylene glycol).

[0249] In some embodiments, the poly(ethylene glycol) molecule is a linear polymer. Linear PEGs can be alkylated (e.g., methylated or ethylated) at one end, but they can be incorporated into a conjugate of any one of the formulas disclosed herein using the free end in underivatized hydroxyl form. The molecular weight of linear PEGs can be about 1,000 Da to about 100,000 Da. For example, linear PEGs used herein can be about 100,000 Da, 95,000 Da, 90,000 Da, 85,000 Da, 80,000 Da, 75,000 Da, 70,000 Da, 65,000 Da, 60,000 Da, 55,000 Da, 50,000 Da, 45,000 Da, 40,000 Da, , 35,000 Da, 30,000 Da, 25,000 Da, 20,000 Da, 15,000 Da, 10,000 Da, 9,000 Da, 8,000 Da, 7,000 Da, 6,000 Da, 5,000 Da, 4,000 Da, 3,000 Da, 2,000 Da, and 1,000 Da. In some embodiments, the molecular weight of the linear PEG is about 1,000 Da to about 50,000 Da. In some embodiments, the molecular weight of the linear PEG is about 1,000 Da to about 40,000 Da. In some embodiments, the molecular weight of the linear PEG is about 5,000 Da to about 40,000 Da. In some embodiments, the molecular weight of the linear PEG is from about 5,000 Da to about 20,000 Da.

[0250] In some embodiments, the poly(ethylene glycol) molecule is a branched polymer. For example, the branched PEG can be V-shaped or T-shaped, depending on how the PEG is synthesized. The molecular weight of the branched PEG can be from about 1,000 Da to about 100,000 Da. For example, the branched PEG used herein can be from about 100,000 Da, 95,000 Da, 90,000 Da, 85,000 Da, 80,000 Da, 75,000 Da, 70,000 Da, 65,000 Da, 60,000 Da, 55,000 Da, 50,000 Da, 45,000 Da, 40,000 Da, and the like. The branched PEG may have a molecular weight of about 1,000 Da to about 50,000 Da. In some embodiments, the branched PEG may have a molecular weight of about 1,000 Da to about 40,000 Da. In some embodiments, the branched PEG may have a molecular weight of about 5,000 Da to about 40,000 Da. In some embodiments, the branched PEG may have a molecular weight of about 5,000 Da to about 40,000 Da. In some embodiments, the molecular weight of the branched PEG is from about 5,000 Da to about 20,000 Da.

[0251] In some embodiments, the polyethylene glycol (linear or branched) has an average molecular weight of about 500 Da to about 40,000 Da, about 1,000 Da to about 30,000 Da, about 1,000 Da to about 20,000 Da, or about 5,000 Da to about 20,000 Da.

[0252] In some embodiments, the polymers provided herein (e.g., polyethylene glycol) have the following structural formula: [ka]

[0253] In some embodiments, n is an integer from 1 to 1,000, 1 to 800, 1 to 300, or 1 to 100. In some embodiments, n is selected from 10, 20, 50, 100, 200, 250, 300, 500, 600, and 1000.

[0254] Further examples of suitable polymers can be found, for example, in Chen. S. et al. Polymer 51 (2010) 5283-5293, which is incorporated herein by reference in its entirety.

[0255] Exemplary Compounds Non-limiting examples of compounds provided herein include: [ka] JPEG0007675648000123.jpg207166JPEG0007675648000124.jpg81166, or a pharma- ceutically acceptable salt thereof, wherein Liragluzide is a residue of Liragluzide and Ura is uracil.

[0256] Pharmaceutically acceptable salts In some embodiments, the salts of the compounds of formula (I) or formula (II) disclosed herein are formed between an acidic group of the compound, such as an amino functional group, and a basic group, or between a basic group of the compound and an acidic group, such as a carboxyl functional group. According to another embodiment, the compound is a pharma- ceutically acceptable acid addition salt.

[0257] In some embodiments, acids commonly used to form pharma- ceutically acceptable salts of the compounds of Formula (I) or Formula (II) disclosed herein include inorganic acids such as hydrogen disulfide, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, and phosphoric acid, and organic acids such as para-toluenesulfonic acid, salicylic acid, tartaric acid, bitartaric acid, ascorbic acid, maleic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, para-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, and acetic acid, and related inorganic and organic acids. Accordingly, such pharma- ceutically acceptable salts include, but are not limited to, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1, These include 6-dioate, benzoate, chlorobenzoate, methylbenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, and other salts. In one embodiment, pharma- ceutically acceptable acid addition salts include those formed with mineral acids such as hydrochloric acid and hydrobromic acid, especially those formed with organic acids such as maleic acid.

[0258] In some embodiments, bases commonly used to form pharma- ceutically acceptable salts of the compounds of Formula (I) or Formula (II) disclosed herein include hydroxides of alkali metals including sodium, potassium, and lithium; hydroxides of alkaline earth metals such as calcium and magnesium; hydroxides of other metals such as aluminum and zinc; ammonia, unsubstituted or hydroxyl-substituted mono-, di-, or tri-alkylamines, organic amines such as dicyclohexylamine; tributylamine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-(C1-C6)-alkylamines such as N,N-dimethyl-N-(2-hydroxyethyl)amine; morpholine; thiomorpholine; or tri-(2-hydroxyethyl)amine; N-methyl-D-glucamine; morpholine; thiomorpholine; piperidine; pyrrolidine; and amino acids such as arginine, lysine, and the like.

[0259] In some embodiments, the compounds of Formula (I) or Formula (II) disclosed herein, or pharma- ceutically acceptable salts thereof, are substantially isolated.

[0260] In some embodiments, the present application provides a compound of formula (I) or formula (II) disclosed herein, or a pharma- ceutically acceptable salt thereof, prepared by any one of the processes described herein.

[0261] Hydrolytic cascade The conjugate provided herein advantageously provides the release of GLP-1 polypeptide or its analogue.In some embodiments, the release of drug occurs under physiological conditions.In some embodiments, the compound undergoes selective cleavage of one or more chemical bonds.Without being bound by any particular theory, it is believed that the conjugate can provide the release of GLP-1 polypeptide or its analogue according to any one of the mechanisms described in the following schemes. Scheme 4 [ka]

[0262] Compounds of formula (I) or (II) can undergo a hydrolytic cascade to give the biologically active drug HZ, as depicted in Scheme 4. 3 With reference to Scheme 4, when a compound of Formula (I) or Formula (II) is subjected to physiological pH, acidic pH, or enzymatic conditions as described herein, moiety E is selectively cleaved, leaving compound 2a-1 containing a reactive nucleophilic group -AH (e.g., -OH), which then reacts with the phosphorus atom to produce cyclic compound 2a-2 and a self-immolative group M A Decomposition of the self-immolative group in compound 2a-5 leads to the formation of compound 2a-5, which contains the group M A’ and the biologically active drug HZ 3 This results in the formation of compounds 2a-4 containing -D or HO-(C=O)-D. The cyclic phosphotriester 2a-2 can be further hydrolyzed at physiological pH resulting in the opening of the five-membered ring and the formation of both isomeric phosphodiesters. [ka]

[0263] In some embodiments, compounds of Formula (I) or Formula (II) may undergo a hydrolytic cascade to release a biologically active drug, as depicted in Scheme 5. Scheme 5 [ka]

[0264] In some embodiments, compounds of formula (I) or formula (II) may undergo a hydrolytic cascade to release a GLP-1 polypeptide or an analog thereof, as depicted in Scheme 6. Scheme 6 [ka]

[0265] In some embodiments, M A is of formula (I) or formula (II) is a group of formula (i), then a release cascade can occur according to the mechanism shown in Scheme 7. Scheme 7 [ka]

[0266] In some embodiments, M A When is formula (I) and is a stable diradical of formula (l), a release cascade can occur according to the mechanism shown in Scheme 8. Scheme 8 [ka]

[0267] Exemplary Methods for Studying Cleavage Reaction Ratios An exemplary method for studying the extent of release of a biologically active drug from a conjugate containing a cleavable acyl group is shown in the following scheme: In some embodiments of any of the compounds shown in the scheme, U is an optionally substituted uracil. Scheme 9 [ka]

[0268] Referring to Scheme 9, cleavage of the phosphotriester is followed by reversed-phase (RP) HPLC separation and quantification of the liberated DMTr-hydroxybenzyl alcohol. Scheme 10 [ka]

[0269] Referring to Scheme 10, the progress of the release reaction can be monitored by observing the umbelliferone fluorescence that occurs. Scheme 11 [ka]

[0270] Referring to Scheme 11, the disappearance of fluorescence from the high MW starting material and the formation of the low MW product can be monitored using gel permeation chromatography with fluorescence detection.

[0271] Method of preparation Compounds of formula (I) or (II) The compounds provided herein can be prepared using methods similar to those described in PCT / IB2018 / 051579 (WO2018 / 163131), which is incorporated herein by reference in its entirety.

[0272] Exemplary synthetic methods for preparing compounds of Formula (I) or Formula (II) of the present disclosure are set forth below. Scheme 12 [ka]

[0273] In some embodiments, the present application provides a compound of formula (II): [ka] or a pharma- ceutically acceptable salt thereof, Compounds of formula (II-IV) [ka] formula HZ 3 -D with a biologically active drug, In the formula, R 1 , R 2 , Z 1 , Z 3 ,D, A , A, E, E 1 , LG, and the aliphatic moiety are as described herein.

[0274] In some embodiments, the reaction is carried out in an aqueous solvent.

[0275] In some embodiments, the reaction is carried out in 0.1 to 0.5 M phosphate buffer, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), or carbonate buffer. In some embodiments, the reaction is carried out at a pH of about 7.2 to about 8.5, at about 0° C. to about room temperature, for about 30 minutes to about 12 hours. In some embodiments, the reaction is carried out at ambient temperature.

[0276] In some embodiments, the compound of formula (II-IV) is i) deprotecting the compound of formula (II-Va), [ka] Obtaining a compound of formula (II-Vb), [ka] ii) reacting a compound of formula (II-Vb) with a compound containing a leaving group to prepare a compound of formula (II-IV).

[0277] In some embodiments, the deprotection comprises treating the compound of Formula (II-Va) with an acid.

[0278] In some embodiments, the compound containing a leaving group is an activated carbonate. For example, the activated carbonate has formula (Vc) or formula (Vd) described herein. [ka]

[0279] In some embodiments, the compound of formula (II-Va) is prepared by reacting a compound of formula (II-VIa): [ka] They are prepared by a process which involves reacting with an aliphatic moiety (eg, a polymer) which contains a reactive hydroxyl group.

[0280] In some embodiments, the reaction is carried out in the presence of an activating reagent (e.g., a reagent that reacts stoichiometrically with phosphate to form a mixed anhydride, which is then converted to, for example, methylimidazolide, and finally reacts with the OH group of the polymer). In some embodiments, the activating reagent is mesitylenesulfonyl chloride, mesitylenesulfonylnitrotriazole (MSNT), or tosyl chloride.

[0281] In some embodiments, a compound of formula (II-VIa) is prepared by deprotecting a compound of formula (II-VIb). [ka]

[0282] In some embodiments, the deprotection is performed by removing the phosphate protecting group, PG 1 is selectively removed to give a compound of formula (II-VIa).

[0283] In some embodiments, the deprotection is carried out in the presence of a base. In some embodiments, the base is diisopropylethylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or triethylamine.

[0284] In some embodiments, the compound of formula (II-VIb) is prepared by reacting the compound of formula (II-VIIa): [ka] with a compound of formula (II-VIIb), [ka] wherein each R is independently a C1-C6 alkyl, or two R groups together with the N to which they are attached form a 5- or 6-membered ring. In some embodiments, each R is isopropyl. In some embodiments, two R groups together form a morpholine ring.

[0285] In some embodiments, the reaction is carried out in the presence of an activating reagent, for example, the activating reagent is selected from the group consisting of tetrazole, 2-ethylthiotetrazole, 2-benzylthiotetrazole, 4,5-dicyanoimidazole, activator 42, pyridinium hydrochloride, and pyridinium trifluoroacetate.

[0286] In some embodiments, step 2 of the reaction is carried out in the presence of an oxidizing reagent. For example, the oxidizing reagent converts the phosphorus atom to the oxidation state P +3 to oxidation state P +5 Examples of oxidizing agents include iodine, hydrogen peroxide, t-butyl hydrogen peroxide, or acetone peroxide.

[0287] In some embodiments, the compound of formula (II-VIIa) is prepared by reacting the compound of formula (II-VIIIa) [ka] with a compound of formula (VIIIb), [ka] wherein Hal is a halogen atom (e.g., Cl, Br, or I) and R is as described herein. In some embodiments, Hal is Cl.

[0288] In some embodiments, the reaction is carried out in the presence of a base.

[0289] In some embodiments, Z 3When is not present, compounds of formula (II) can be prepared from compounds of formula (II-Vb), for example, according to Scheme 13. Scheme 13 [ka]

[0290] In some embodiments, compounds of formula (II) can be prepared as described in Scheme 14. Scheme 14 [ka]

[0291] In some embodiments, compounds of formula (II) can be prepared as described in Scheme 15. Scheme 15 [ka]

[0292] In some embodiments, compounds of formula (II) can be prepared as described in Scheme 16. Scheme 16 [ka]

[0293] In some embodiments, M A When is a stable diradical of formula (k-1), compounds of formula (II) can be prepared as described in Scheme 17. Scheme 17 [ka]

[0294] In some embodiments, the present document provides a compound of formula [ka] The present invention provides a method for making a compound of formula (I) or (II), or a pharma- ceutically acceptable salt thereof, having the formula: 1 , R 2 A, E, and D are as described herein, and the method comprises: A compound of the formula [ka] wherein LG is a leaving group as described herein, 3 -D with a GLP-1 polypeptide or an analog thereof.

[0295] In some embodiments, the compound of the formula: [ka] (i) by deprotecting a compound of the formula: 1 is a protecting group as described herein), [ka] Obtaining a compound of formula [ka] (II) reacting the compound obtained in step (i) with a compound containing a leaving group as described herein.

[0296] In some embodiments, the compound of the formula: [ka] (i) reducing a compound of the formula: [ka] Obtaining a compound of formula [ka] (II) reacting the compound obtained in step (i) with a compound containing a leaving group as described herein. Suitable examples of reagents for carrying out the reduction in step (i) include, but are not limited to, NaBH4 and LiAlH4.

[0297] Suitable synthetic methods for starting materials, intermediates, and products can be identified by reference to the literature, including Advances in Heterocyclic Chemistry, Vols. 1-107 (Elsevier, 1963-2012), Journal of Heterocyclic Chemistry Vols. 1-49 (Journal of Heterocyclic Chemistry, 1964-2012), Carreira, et al. (Ed.) Science of Synthesis, Vols. 1-48 (2001-2010), Katritzky et al. (Ed.); Comprehensive Organic Functional Group Transformations II (Elsevier, 2003). nd Edition, 2004), Smith et al., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 6 th Ed. (Wiley, 2007), Trost et al. (Ed.), Comprehensive Organic Synthesis (Pergamon Press, 1991).

[0298] Preparation of the compounds provided herein can involve the protection and deprotection of various chemical groups. Protective group chemistry is described, for example, in PGM Wuts and T.W. Greene, Protective Groups in Organic Synthesis, 4 thEd., Wiley & Sons, Inc., New York (2006). Chemistry and protecting group strategies related to nucleosides and nucleotides can also be found in Methods in Molecular Biology-Oligonucleotide Synthesis edited by Piet Herdewijn (Humana Press Inc. 2005) and Protocols for oligonucleotide conjugates edited by Sudhir Agrawal (Humana Press Inc. 1994). Suitable starting materials and intermediates are readily available from a variety of commercial sources.

[0299] Methods of Use of the Disclosed Compounds Methods of Treating a Disease or Condition In some embodiments, the disclosure provides a method for treating a disease, disorder, or condition in a mammal (e.g., a human in need of such treatment), comprising administering to the mammal a compound of Formula (I) or Formula (II) disclosed herein, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising same.

[0300] For example, the compounds of the present disclosure are useful in treating a disease or condition that is beneficially treated by administering to a subject a GLP-1 polypeptide or analog thereof described herein.

[0301] In some embodiments, compounds of the present disclosure are useful in reducing food intake by a subject, for example, by controlling or suppressing the subject's appetite.

[0302] In some embodiments, the disease or condition is obesity.

[0303] In some embodiments, the disease or condition is diabetes, including type 1 diabetes, type 2 diabetes, gestational diabetes, surgery-induced diabetes, and chemically-induced diabetes, as well as latent autoimmune diabetes in adults (LADA or type 1.5 diabetes).

[0304] Combination therapy One or more additional agents or therapeutic methods can be used in combination with any one of the conjugates described herein for the treatment of the diseases, disorders, or conditions described herein. The agents can be combined with the compound in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.

[0305] Suitable additional agents contemplated for use in combination with the compounds of the present disclosure may include any one of the GLP-1 polypeptides or analogs thereof described herein.

[0306] Non-limiting examples of additional medications include insulin (e.g., fast-acting insulin (works within minutes and lasts 2-4 hours); regular or short-acting insulin (works within 30 minutes and lasts 3-6 hours); intermediate-acting insulin (works within 1-2 hours and lasts up to 18 hours); long-acting insulin (works within 1-2 hours and lasts for more than 24 hours); very long-acting insulin (works within 1-2 hours and lasts for 42 hours)); AFREZZA® (inhaled insulin); TRESIBA® (insulin degludec and insulin aspart injection); RYZODEG® 70 / 30 (insulin degludec and insulin aspart injection); LEVEMIR® (insulin detemir); LANTUS (insulin glargine); BYETTA® (exenatide; exenden-4); VICTOZA® (liraglutide); SAXENDA® (liraglutide); AL BIGLUTIDE® (Tanzm, Eperzan); TRULICITY® (dulaglutide); OZEMPIC® (semaglutide); drugs that increase insulin production by the pancreas, including chlorpropamide (Diabinese®), glimepiride (Amaryl®), glipizide (Glucotrol®), glyburide (Diabeta®, Glynase®), nateglinide (Starlix®), and repaglinide (Prandin®); drugs that decrease sugar absorption by the intestine, such as acarbose (Precose®), miglitol (Glyset®); drugs that improve how the body uses insulin, such as pioglitazone (Actos®) and rosiglitazone (Avandia®); drugs that decrease sugar production by the liver and improve insulin resistance, such as metformin (Glucophage®);Medications that increase insulin production by the pancreas and reduce its blood levels and / or glucose production from the liver, including alogliptin (Nesina®), dulaglutide (Trulicity®), linagliptin (Tradjenta®), exenatide (Byetta®, Bydureon®), liraglutide (Victoza®), lixisenatide (Adlyxin®), saxagliptin (Onglyza®), sitagliptin (Januvia®), and semaglutide (Ozempic®); canaglifozin (Invokana®), dapagliflozin (Farxil®), and rifagliflozin (Ricin®); Drugs that block glucose reabsorption by the kidneys and increase glucose excretion in the urine, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, including iga®, and empagliflozin (Jardiance®); pramlinitide (Symlin®); empagliflozin / linagliptin (Glyxambi®); orlistat (XENICAL®); lorcaserin (BELVIQ®); phentermine-topiramate (QSYMIA®); naltrexone-bupropion (CONTRAVE®); phentermine; benzphetamine; diethylpropion; and phendimetrazine.

[0307] In some embodiments, the methods provided herein may include a combination of two or more compounds provided herein. For example, the two compounds may have different release profiles (e.g., a longer T1 / 2 and a shorter T1 / 2).

[0308] Methods for the safe and effective administration of most of these drugs are known to those skilled in the art. In addition, their administration is described in standard texts. For example, the administration of many drugs is described in the "Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ), the disclosure of which is incorporated herein by reference as if set forth in its entirety.

[0309] Pharmaceutical Compositions and Formulations The present application also provides a pharmaceutical composition comprising an effective amount of any one of the compounds of formula (I) or formula (II) disclosed herein or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier. The carrier(s) are "acceptable" in the sense of being compatible with the other ingredients of the formulation and, in the case of a pharma- ceutical acceptable carrier, not deleterious to the recipient thereof in the amounts employed in the medicament.

[0310] Pharmaceutically acceptable carriers, adjuvants, and vehicles that may be used in the pharmaceutical compositions of the present application include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffers (such as phosphoric acid), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes (such as protamine sulfate), disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat.

[0311] The composition or dosage form may contain a compound of formula (I) or formula (II) described herein in the range of 0.005% to 100%, with the remainder consisting of suitable pharma- ceutically acceptable excipients. Contemplated compositions may contain 0.001% to 100%, in one embodiment 0.1 to 95%, in another embodiment 75 to 85%, and in a further embodiment 20 to 80% of a compound of formula (I) or formula (II) provided herein, with the remainder consisting of any pharma- ceutically acceptable excipient described herein, or any combination of these excipients.

[0312] Route of administration and dosage form Pharmaceutical compositions of the present application include those suitable for any accepted route of administration. Acceptable routes of administration include, but are not limited to, intraoral, intradermal, intracervical, intrasinus, intratracheal, enteral, epidural, intrainterstitial, intraperitoneal, intraarterial, intrabronchial, intravesical, intracerebral, intracisternal, intracoronary, intradermal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intraileal, intralymphatic, intramedullary, intrameningeal, intramuscular, intranasal, intraovarian, intraperitoneal, intraprostatic, intrapulmonary, intranasal, intraspinal, intrasynovial, intratesticular, intramedullary, intrathecal, intraductal, intratumor, intrauterine, intravascular, intravenous, intranasal, nasogastric, oral, parenteral, transdermal, epidural, rectal, respiratory (inhalation), subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, transtracheal, ureteral, urethral, ​​and intravaginal.

[0313] The compositions and preparations described herein can be conveniently provided in unit dosage form, for example, tablets, sustained release capsules, and liposomes, and can be prepared by any method well known in the field of pharmacy.See, for example, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, Baltimore, MD (20th ed.2000).Such preparation methods include the step of bringing ingredients such as carriers that are associated with the molecule to be administered and constitute one or more accessory ingredients.In general, the composition is prepared by uniformly and intimately associating active ingredient with liquid carriers, liposomes, or finely divided solid carriers, or both, and then forming the product as necessary.

[0314] In some embodiments, the compound of formula (I) or formula (II) disclosed herein is administered orally. The composition of the present application suitable for oral administration may be presented as separate units such as capsules, sachets, granules or tablets, each containing a predetermined amount (e.g., effective amount) of active ingredient, powder or granules, solution or suspension in aqueous liquid or non-aqueous liquid, oil-in-water liquid emulsion, water-in-oil liquid emulsion, loading into liposome, or bolus, etc. Soft gelatin capsules may be useful to contain such suspensions, which may beneficially increase the absorption rate of the compound. For tablets for oral use, commonly used carriers include lactose, sucrose, glucose, mannitol, and silicic acid and starch. Other acceptable excipients include: a) fillers or extenders such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrants such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarders such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) humectants such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay; and i) lubricants such as talc, calcium stearate, magnesium stearate, stearates, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. For oral administration in capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspension is administered orally, active ingredient is combined with emulsifier and suspending agent.Optionally, certain sweetener and / or flavoring and / or coloring agent can be added.The composition suitable for oral administration includes lozenges that contain flavor base ingredient, usually sucrose and acacia or tragacanth, and pastilles that contain active ingredient in inert base such as gelatin and glycerin, or sucrose and acacia.

[0315] Compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection or infusion solutions, which may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, as well as aqueous and non-aqueous sterile suspensions, which may contain suspending agents and thickening agents. The formulations may be provided in single-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) state, requiring only the addition of a sterile liquid carrier, for example water for injection, saline or 5% dextrose solution, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets. The injection solutions may be in the form of, for example, a sterile injectable aqueous or oleaginous suspension. The suspensions may be formulated using suitable dispersing or wetting agents and suspending agents according to techniques known in the art. The sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally acceptable diluents or solvents, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be used are mannitol, water, Ringer's solution, and isotonic sodium chloride solution.In addition, sterile, fixed oils are conventionally used as solvents or suspending media.For this purpose, any non-irritating fixed oils, including synthetic mono- or diglycerides, can be used.Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injections, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.These oil solutions or suspensions can also contain long-chain alcohol diluents or dispersants.

[0316] The pharmaceutical composition of the present application can be administered in the form of suppositories for rectal administration.These compositions can be prepared by mixing the compound of the present application with suitable non-irritating excipients that are solid at room temperature but liquid at rectal temperature, and therefore melt in the rectum to release active ingredient.Such materials include, but are not limited to, cocoa butter, beeswax, and polyethylene glycol.

[0317] The pharmaceutical compositions of the present application can be administered by nasal aerosol or inhalation. Such compositions can be prepared according to well-known techniques in the field of pharmaceutical formulations, and can be prepared as solutions in saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other solubilizing or dispersing agents known in the art. For example, see U.S. Patent No. 6,803,031. Additional formulations and methods for intranasal administration can be found in Ilium, L., J Pharm Pharmacol, 56:3-17, 2004 and Ilium, L., Eur J Pharm Sci 11:1-18, 2000.

[0318] The topical compositions of the present disclosure can be prepared and used in the form of aerosol sprays, creams, emulsions, solids, liquids, dispersions, foams, oils, gels, hydrogels, lotions, mousses, ointments, powders, patches, pomades, solutions, pump sprays, sticks, towelettes, soaps, or other forms commonly used in the field of topical administration and / or cosmetic and skin care formulations.The topical composition can be in the form of an emulsion.Topical administration of the pharmaceutical compositions of the present application is particularly useful when the desired treatment involves areas or organs easily accessible by topical application. In some embodiments, topical compositions comprise a combination of a compound of Formula (I) or Formula (II) disclosed herein and one or more additional ingredients, carriers, excipients, or diluents, including, but not limited to, absorbents, anti-irritants, anti-acne agents, preservatives, antioxidants, colorants / pigments, emollients (moisturizers), emulsifiers, film formers / retentive agents, fragrances, leave-on scrubs, prescription drugs, preservatives, scrubbing agents, silicones, skin identity / repair agents, slip agents, sunscreen actives, surfactants / detergents, cleaning agents, penetration enhancers, and thickeners.

[0319] The compounds of the present application can be incorporated into compositions to coat implantable medical devices, such as prostheses, artificial valves, vascular grafts, stents, or catheters. Suitable coatings and the general preparation of coated implantable devices are known in the art and are exemplified in U.S. Pat. Nos. 6,099,562, 5,886,026, and 5,304,121. Coatings are typically biocompatible polymeric materials, such as hydrogel polymers, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. Coatings can optionally be further covered by a suitable topcoat of fluorosilicone, polysaccharides, polyethylene glycol, phospholipids, or combinations thereof to impart controlled release properties to the composition. Coatings for invasive devices should be included within the definition of pharma-ceutically acceptable carrier, adjuvant, or vehicle, as those terms are used herein.

[0320] According to another embodiment, the present application provides an implantable drug release device impregnated or containing a compound of the present application or a composition comprising a compound of the present application, whereby the compound is released from the device and is therapeutically active.

[0321] Dosage and Regimen In the pharmaceutical compositions of the present application, the compounds of formula (I) or formula (II) disclosed herein are present in an effective amount (eg, a therapeutically effective amount).

[0322] The effective dose may vary depending on the disease being treated, the severity of the disease, the route of administration, the sex, age, and general health of the subject, excipient usage, the possibility of co-use with other therapeutic treatments, e.g., the use of other agents, and the judgment of the treating physician.

[0323] In some embodiments, an effective amount of a compound of Formula (I) or Formula (II) disclosed herein can be, for example, from about 0.001 mg / Kg to about 500 mg / Kg (e.g., from about 0.001 mg / Kg to about 200 mg / Kg; from about 0.01 mg / Kg to about 200 mg / Kg; from about 0.01 mg / Kg to about 150 mg / Kg; from about 0.01 mg / Kg to about 100 mg / Kg; from about 0.01 mg / Kg to about 50 mg / Kg; from about 0.01 mg / Kg to about 10 mg / Kg; from about 0.01 mg / Kg to about 5 mg / Kg; from about 0.01 mg / Kg to about 10 mg / Kg; mg / Kg to about 1 mg / Kg; about 0.01 mg / Kg to about 0.5 mg / Kg; about 0.01 mg / Kg to about 0.1 mg / Kg; about 0.1 mg / Kg to about 200 mg / Kg; about 0.1 mg / Kg to about 150 mg / Kg; about 0.1 mg / Kg to about 100 mg / Kg; about 0.1 mg / Kg to about 50 mg / Kg; about 0.1 mg / Kg to about 10 mg / Kg; about 0.1 mg / Kg to about 5 mg / Kg; about 0.1 mg / Kg to about 1 mg / Kg; about 0.1 mg / Kg to about 0.5 mg / Kg).

[0324] The aforementioned dosages can be administered daily (e.g., as a single dose or as two or more divided doses, e.g., once a day, twice a day, three times a day) or non-daily (e.g., every other day, every second day, every third day, once a week, twice a week, once every two weeks, once a month).

[0325] kit The present invention also includes pharmaceutical kits, useful, for example, in the treatment of disorders, diseases, and conditions mentioned herein, which include one or more containers containing a therapeutically effective amount of a pharmaceutical composition comprising a compound of the present disclosure.Such kits can further include one or more of various conventional pharmaceutical kit components, as desired, for example, a container with one or more pharma-ceutically acceptable carriers, additional vessels, etc.Instructions, either as inserts or labels, indicating the amount of components to be administered, guidelines for administration, and / or guidelines for mixing components, can also be included in the kit. EXAMPLES

[0326] All reagents were obtained from known commercial suppliers unless otherwise stated. Standard laboratory and analytical procedures were employed unless otherwise stated.

[0327] Example 1 - Synthesis of FMOC-based liraglutide conjugates [ka] Step 1. Reacting FMOC-Cl with aminouridine to give carbamate 1 2'-Aminouridine (1 mol equiv.) was dissolved in water (10 ml / mmol), a mixture of 1M aqueous NaHCO3 (3 mol equiv.) and approximately 20% dioxane was added and the mixture was cooled to 0°C. Fluorenylmethyl chloroformate (2 mol equiv.) was dissolved in dry dioxane and added dropwise to the cooled solution. The solubility of the reaction mixture was adjusted by the addition of dioxane. After stirring for 1 h, chloroformic acid (1 mol equiv.) was added and the mixture was stirred for another 1 h. The cooling was removed and the aqueous reaction mixture was extracted three times with 10% MeOH / DCM. The organic phase was evaporated to dryness. The residue was chromatographed through silica gel 60A using a MeOH-DCM gradient (2-4-6%) to isolate 2'-N-(fluorenylmethylcarbamoyl)uridine (2'-N-(FMOC)uridine) as a white solid (65-75% yield).

[0328] Step 2. Method for 5'-O-pivaloylation of uridine 2'-N-carbamate 1 to obtain 5'-O-pivaloyl uridine-2'-N-carbamate 2 Compound 1 (1 mol equiv.) was dried by coevaporation with dry pyridine, the residue was dissolved in dry pyridine (2.5 mL / mmol) and cooled to 0 °C. Pivaloyl chloride (1.2 mol equiv.) was dissolved in dichloromethane (2.5 mL / mmol) and slowly added to the pyridine solution. After complete addition, the mixture was stirred at room temperature for 15 h (overnight). The reaction was quenched with MeOH, and after a few minutes the mixture was partitioned between 0.2 M phosphoric acid (pH 7.0) and dichloromethane. The oily residue was purified by chromatographic evaporation of the organic phase using a gradient of DCM / MeOH (0-2-3-4% MeOH / DCM, product comes at 3-4% MeOH) and coevaporation with toluene through silica gel 60A to give product 2 in the form of a white foam (yield 70-80%).

[0329] Step 3. Preparation of phosphodiester compound 3 Preparation of 4-(4,4'-dimethoxytrityloxymethyl)phenol Compound 3 was produced using a method similar to that published in Iyer, RP et al. Tetrahedron Letters, 2001, 42, 3669-3672. Briefly, 4-hydroxybenzyl alcohol (1 mol equiv.) was dissolved in dry pyridine (10 mL / mol). 4,4'-dimethoxytrityl chloride (1.1 mol equiv.) was dissolved in dry DCM (approximately 5 mL / mmol) and this solution was added dropwise from a dropping funnel to the pyridine solution with stirring. After complete addition, the reaction solution was stirred at room temperature for at least 16 hours.

[0330] Work-up and purification: The reaction was quenched by adding MeOH and after stirring for a while the solvent was evaporated. The residue was dissolved in DCM and the organic phase was extracted with saturated aqueous NaHCO3. The aqueous phase was extracted twice more with DCM. The combined DCM phases were evaporated and the residue was co-evaporated with toluene. The residue was chromatographed through silica gel 60A using a gradient of ethyl acetate (EtAc) / petroleum ether (PetEt) (eluted with 20-30-50% EtAc / PetEt+0.1% pyridine, 30-50% EtAc) to give the product phenol in high yield. 1 H-NMR,500MHz (CDCl3):7.51-6.80(m,17H),4.61(br,s,1H)OH,4.07(br s,2H)CH2,3.78(s,6H)2 x OMe.

[0331] Triethylammonium salt of phosphodiester compound 3. (4-(4,4'-dimethoxytrityloxymethyl)phenol (1.0 mol equiv.) in dry MeCN solution (7 mL / mmol) plus dry pyridine (3.5 mL / mmol) was added slowly dropwise to a vigorously stirred 0.2 M solution of tristriazolide phosphite (1.1 mol equiv.) in dry MeCN under nitrogen. The resulting solution was stirred at room temperature under nitrogen for approximately 1-1.5 hours.

[0332] A solution of compound 2 (0.95 mol equiv.) in dry MeCN (9 mL / mmol) was added dropwise to the mixture and the newly obtained mixture was stirred at room temperature for about 2 h. The reaction was quenched with 1 M triethylammonium bicarbonate (approximately 8 mL / mmol scale) and the mixture was concentrated on a rotary evaporator. The remaining concentrate was poured into 1 M triethylammonium bicarbonate and extracted three times with DCM. The solution was evaporated. The residue was chromatographed through silica gel 60A using a gradient of DCM / EtOH (0-4-8-10-15-20% EtOH / DCM + 0.1% pyridine, product eluted with 8-15% EtOH) to give O-aryl-O-alkyl phosphodiesters 3 as triethylammonium salts (50-65% yield).

[0333] Step 4. Method for the preparation of MeOPEG phosphotriester compound 4 The phosphodiester 3 (1 mol equiv.), mPEG-OH (3 mol equiv.), and N-methylimidazole (24 mol equiv.) were dissolved in dry MeCN and evaporated to dryness. The residue was concentrated with another round of coevaporation with dry MeCN to less than 5 mL / mmol MeCN (semi-viscous). A concentrated MeCN solution (1.25 mL / mmol) of 1-mesitylenesulfonyl chloride (12 mol equiv.) was added dropwise while swirling the viscous solution. After addition, the solution was rotated in a round bottle at room temperature for 66-72 h (to ensure that all material inside the flask wall is involved in the reaction; a shaking apparatus can also be used).

[0334] The reaction mixture was quenched with MeOH and the mixture was evaporated to dryness on a rotary evaporator. The residue was recrystallized from isopropanol (approximately 13 mL / g of PEG was used; the mixture was kept at 55° C. to dissolve the solid material, and the PEGylated material crystallized upon cooling to room temperature). The solid mass was recrystallized on a P3 or P4 glass sintered filter, washed with cold isopropanol, and finally with diethyl ether, and dried under vacuum.

[0335] The crude solid was treated with C 18 Analysis by RP-HPLC verified the presence of triester product 4. The major UV-Vis by-product had a shorter R bond than the product triester 4. t There is reason to believe that all the free hydroxyls in mPEG were consumed by either phosphorylation or sulfonylation. 18 Depending on the size of the RP HPLC column, the triester 4 can be separated in batches from the by-products using the following solvent mixtures and gradients: Sample diluent: 20% MeCN in water Buffer A: 0.1 M triethylammonium acetate / 5% MeCN in water. Buffer B: 100% MeCN Gradient: 30-60% B over 60 min. Monitoring: 270nm

[0336] The collected fractions were pooled, evaporated to dryness, and the residue was kept under high vacuum for several hours. The sticky residue (45-55% yield) was used in step 5.

[0337] Step 5. Method for the Preparation of MeOPEG Phosphotriester Hydroxyl Blocked Compound 5 4-(4,4'-dimethoxytrityloxymethyl)phenylphosphotriester Compound 4 (1 mol equiv.) was dissolved in 80% acetic acid (approximately 350 mL / mmol) and the solution was kept at room temperature for 2 h. Volatiles were evaporated and the residue was coevaporated with toluene. The residue was recrystallized from isopropanol as described in step 4 to give O-alkyl-O-(mpegyl)-O-[(4-hydroxymethyl)phenyl]phospho-triester 5, which was used directly in the next step 6.

[0338] Step 6. Method for the preparation of MeOPEG phosphotriester NHS carbonate compound 6 The above hydroxyl block (1 mol equiv.) was dissolved in dry DCM (140 μL / μmol), then 15 wt. % phosgene (190 mol equiv.) was added and the solution was stirred at room temperature for 2-3 h. The volatiles were evaporated and the residue was coevaporated with toluene several times.

[0339] Crude chloroformic acid (1 mol equiv.) was dissolved in dry THF (6 mL / mmol) and dry DCM (1.2 mL / mmol). N-hydroxysuccinimide (75 mol equiv.) was then added, followed by dry pyridine (100 mol equiv.) and the mixture was stirred at room temperature for 2 h. The mixture was evaporated to dryness and the residue was coevaporated with toluene (at least three times), then the residue was triturated with diethyl ether, the supernatant was decanted and the solid was dried under vacuum. This gave O-alkyl-O-mPEGyl-O-[4-(NHS-carbonyloxy-methyl)phenyl]phosphotriester 6. C18 RP-HPLC analysis showed one broad homogenous peak corresponding to product 6. Another single peak at the beginning of the chromatogram was excess NHS. Sample diluent: 20% MeCN in water Buffer A: 0.1% TFA / 5% MeCN in water. Buffer B: 0.1% TFA in MeCN Gradient: 30-60% B over 60 min (for column size 250x10mm) Monitoring: 270 nm (also 254 nm for parallel channels)

[0340] Step 7. Method for preparation of releasable MeOPEG-liraglutide conjugate 7 (mPEG-liraglutide) Liraglutide (1 mg, 0.27 μmol, SEQ ID NO: 3) was dissolved in 0.3 M HEPES buffer (pH 7.4, 400 μL) and MeCN (20 μL) in a 2 mL plastic screw-cap vial. Solid compound 6 (24 mg, 0.81 μmol) was then added, the solid was dissolved by occasional sonication (1-2 s per time, approximately 3-4 times), and the solution was stirred at room temperature for 2-2.5 h.

[0341] Work-up: The reaction mixture was diluted to 1 mL with deionized water (or distilled water) and quenched by acidifying with 80% AcOH (pH 3-4). If necessary, the solution was filtered through a 0.45 μm disk filter before injection into the HPLC column. Using a column (RP 250 x 10 mm) and gradient system as in step 6, the conjugate was identified as a broad peak in the 50-55 min region. Unreacted liraglutide eluted around 60 min. All other components eluted earlier than 45 min.

[0342] The product fractions were collected, pooled and evaporated. The glassy residue was then dissolved in a small amount of 20% MeCN / water and lyophilized (94 nmol, 35%).

[0343] In the following experiments, the T1 / 2 at pH 8 is calculated to be about 11 hours, which converts to 44 hours at pH 7.4 (factor 4X). Approximately 1 mg of conjugate was dissolved in a volume of 20% MeCN in water. An appropriate amount of azidothymidine (AZT) was added as an internal standard, and hydrolysis was initiated by adding a volume of 0.3 M TRIS buffer at pH 8.0. The reaction mixture was then maintained at 37°C. Aliquots of 30 μL were taken at each time point and acidified by the addition of 20 μL of 1 M AcOH before injection into the HPLC.

[0344] Example 2 - CPSEC-based Liraglutide Conjugate 8 Using a method similar to that described in Example 1, CPSEC-based liraglutide conjugate 8 was prepared. [ka]

[0345] In Tris buffer at pH 8 and 37° C., compound 8 has a pH-induced T1 / 2 of approximately 2.5 hours (measured as described in Example 1).

[0346] Example 3 - FMOC derivative (1-fluorenylethoxycarbonyl) based conjugate of liraglutide 9 Using a method similar to that described in Example 1, FMOC derivative (1-fluorenylethoxycarbonyl)-based conjugate 9 of liraglutide was prepared. [ka]

[0347] In Tris buffer at pH 7.4 and 37°C, compound 9 is estimated to have a pH-induced T of approximately 36 days. This estimate is based on hydrolysis of compound 1 (the FEC group), a process outlined in Tester 1. This results in a T of approximately 36 days at pH 8. 1 / 2 This turned out to be close to one month (27 days). Multiplying by a factor of 4 (factor 4X), at pH 7.4, gives us 4 months (2560 hours). Previous experiments have shown that the T 1 / 2 and T of the final conjugate 1 / 2 It has been observed that there is an approximate factor of 3X between 0.01 and 0.1 (presumably due to the influence of the phosphotriester group), giving 2560 hours / 3 = 854 hours (36 days).

[0348] Example 4 - DPEC-based Liraglutide Conjugate 10 Using a method similar to that described in Example 1, DPEC-based liraglutide conjugate 10 was prepared. [ka]

[0349] Hydrolysis of compound 1 gave a T1 / 2 of 12 days at pH 8, and based on the calculations detailed in Example 3, an estimated T1 / 2 of 16 days was obtained for compound 10 at pH 7.4.

[0350] Example 5 - FPEC (fluorenylphenylethoxycarbonyl) based conjugate of liraglutide 11 Using a method similar to that described in Example 1, FPEC (fluorenylphenylethoxycarbonyl)-based conjugate 11 of liraglutide was prepared. [ka]

[0351] Example 6 - DFDPEC-based Liraglutide Conjugate 12 Using a method similar to that described in Example 1, DFDPEC-based liraglutide conjugate 12 was prepared. [ka]

[0352] Example 7 - DTBFMOC-based Liraglutide conjugate 13 Using a method similar to that described in Example 1, DTBFMOC-based liraglutide conjugate 13 was prepared. [ka]

[0353] Example 8 - Preparation of conjugates of liraglutide using phosphodichloridate methodology for the synthesis of PEG reagents [ka] Steps 1 to 2. Steps 1 and 2 are carried out according to the same methods and procedures as in Example 1.

[0354] Step 3. Method for the preparation of N3-benzoylated 5'-O-pivaloyluridine-2'-N-carbamate 8-2. Compound 2 (1 equiv.) was dissolved in dry pyridine (7 mL / mmol). Chlorotrimethylsilane (TMS-Cl, 3 equiv.) was added to the pyridine solution at room temperature and the mixture was stirred at room temperature for 1 h. Benzoyl chloride (2 equiv.) was then added and the mixture was stirred for 2 days. The reaction mixture was quenched with methanol and after 15 min it was concentrated on a rotary evaporator and partitioned between saturated aqueous sodium bicarbonate and dichloromethane. After evaporation of the organic phase, the residual oil was coevaporated with toluene to remove traces of pyridine. The residue was dissolved in 80% AcOH (10 mL / mmol) and stirred for 10 min to cleave the silyl ether, followed by rotary evaporation to dryness and coevaporation with toluene. The residue was chromatographed through silica gel 60A using a gradient of MeOH in DCM (0-2-4%) to give the product 8-2 as a white solid. The isolated yield was typically around 80%.

[0355] Step 4. Preparation of the triethylammonium salt of phosphodiester compound 3. A solution of 4-formylphenyl phosphorodichloridate (2 equiv.) was prepared according to Engberts, JBFNet al. Langmuir 1996,12,5773-5780, used crude without distillation, dissolved in dry MeCN (1 mL / mmol) and added dropwise to compound 8-2 (1 equiv.) dissolved in dry pyridine (4 mL / mmol). The resulting mixture was stirred at room temperature for about 2 h. The reaction was quenched with 1 M triethylammonium bicarbonate and extracted three times with DCM. The organic phase was evaporated and dried by coevaporation with toluene, and the residue was chromatographed through silica gel 60A with a gradient of DCM / MeOH (0-2-4-6-8% MeOH / DCM+0.1% pyridine). The product was eluted with 4-6% MeOH to give O-aryl-O-alkyl phosphodiesters 3 as triethylammonium salts (50-65% isolated yield).

[0356] Step 5. Preparation of MeOPEG phosphotriester aldehyde 4 The phosphodiester 3 (1 equiv.), pre-dried mPEG-OH (3 equiv.), and N-methylimidazole (24 equiv.) were dissolved in dry MeCN and evaporated to dryness. The residue was once again co-evaporated with dry MeCN and concentrated to a semi-viscous MeCN solution. To this solution was added a solution of 1-mesitylenesulfonyl chloride (12 equiv.) in a minimum amount of dry MeCN in one portion. After the addition, the reaction mixture in a round-bottom flask was shaken at room temperature for 16 h.

[0357] The reaction mixture was quenched with MeOH and concentrated to dryness on a rotary evaporator. The residue was recrystallized from isopropanol (40 mL / 3 gm PEG). The mixture was heated at 55° C. to dissolve the solid material. The PEGylated material crystallized upon cooling to room temperature. The crystallized material was filtered on a glass sinter filter, washed with cold isopropanol, followed by diethyl ether, and dried under vacuum (yields are usually close to the amount of mPEG-OH used in the reaction).

[0358] The crude solid was treated with C 18 Analysis by RP-HPLC verified the presence of the phosphotriester product 4. The product usually appears as the largest peak in the chromatogram and has the characteristic broadness typical of all PEG-containing materials. The crude material was used directly in the next step. No purification was performed in this step due to the risk of conversion to a hydrate on contact with water.

[0359] Step 6. Method for the preparation of MeOPEG phosphotriester hydroxyl blocked compound 5. The crude aldehyde phosphotriester 4 (3.5 g, 0.059 mmol) was dissolved in MeCN (15 mL) and the solution was poured into water (70 mL) in a glass beaker with stirring. A glass rod from a pH meter was left immersed in the resulting solution. NaBH4 (5 equiv.) was then immediately added portionwise with a spatula and the increase in pH was monitored. Gas evolution also began. After complete addition, the pH reached about 8.9 within a few minutes. At this time, 1 M citric acid was added dropwise to lower the pH to about 6.5-6.6.

[0360] The resulting clear solution was evaporated with the addition of some n-butanol as an antifoaming agent. The residue was dissolved in MeCN, stirred for 5 min, and the fine suspension was filtered through Celite. The clear filtrate was then evaporated and dissolved in 30% acetonitrile / water solution.

[0361] Preparative RP HPLC (Lichrospher 100 RP-18) separated triester 5 from by-products using the following solvent mixtures and gradients: Buffer A: 0.1 M triethylammonium acetate in 5% MeCN / water. Buffer B: 100% MeCN Gradient: 30-60% B over 60 min. Monitoring: 270nm

[0362] The collected fractions were pooled together, evaporated to dryness, and the residue was kept under high vacuum for several hours. The sticky residue of pure compound 5 and the residual triethylammonium acetate buffer were dissolved in hot isopropanol (55° C.), and compound 5 crystallized upon cooling as a white solid. The yield was 60%.

[0363] Steps 7-9. The conversion of compound 5 to the NHS carbonate derivative 6 and its conjugation with liraglutide to produce the final conjugate 14 proceeded similarly to the relevant steps presented in Example 1. The final conjugation mixture containing 0.3 M HEPES buffer was diluted with water (10x) and applied to an anion exchange column (OptioBio 40Q 10x100-Bio-Works, Uppsala Sweden) equilibrated in 20 mM phosphate buffer (pH 7.0). Separation was performed starting at isocratic conditions using buffer A-20 mM phosphate buffer pH 7.0. This was continued for 15 min until the uncharged excess PEGylation reagent was eluted following a linear gradient from buffer A to buffer B (20 mM phosphate buffer pH 7.0 + 1.0 M NaCl). Fraction B, representing the conjugate of liraglutide, was collected, concentrated 10-fold by evaporation on a rotary evaporator and acidified to pH 5 by addition of 1 M acetic acid. This material was further purified on a Superdex 200 Increase 10 / 300SEC column using 0.01 M phosphate buffer (pH 7.4) containing 0.14 M NaCl, operating at a flow rate of 0.5 mL / min at room temperature. Samples up to 2.5 mL were injected without substantial loss of peak resolution. Collected fractions containing the pure conjugate were preserved by adding 2 volumes of 0.3 M citrate buffer (pH 4). Pure liraglutide-PEG conjugate 14 obtained during SEC separation. On the same system, free liraglutide showed a retention time of 29 min.

[0364] Example 9 - Preparation of liraglutide conjugates with lipophilic protection of uracil. [ka] Following methods and procedures similar to those described in Example 8, conjugate 15 was obtained.

[0365] Example 10 - Preparation of conjugates of liraglutide with a hydrophobic 5'-DMTr group. [ka] Following methods and procedures similar to those described in Example 8, conjugate 16 was obtained.

[0366] Example 11 - Proteolytic stability and biological activity of compound 7 Analysis of the proteolytic stability of liraglutide and compound 7 in the presence of the protease dipeptidyl peptidase IV (DPP-IV) was analyzed by LC-ESI-MS.

[0367] Liraglutide (SEQ ID NO: 3) was dissolved in 10 mM Na2HPO4 (pH 7.4) to a concentration of 10 mg / mL. Compound 7 was dissolved in 50 mM ammonium acetate buffer (pH 4.5) to a concentration of 10 mg / mL.

[0368] Both samples were diluted with 10 mM Na2HPO4 (pH 7.4) to a protein concentration of 2.67 μM and digested in the presence of 50 mU / mL DPP-IV (porcine kidney, Merck) at 37 °C. Samples were taken 9-5 after 2, 10, 24, 34, 48, 72, and 96 hours. To stop the reaction, 57 μL samples were acidified with 3 μL 10% TFA and stored at -20 °C until measurements were performed.

[0369] Samples were separated on a LaChrom Ultra HPLC system (VWR) using a reversed-phase column (MAbPac RP 4 μm 2.1 × 100 mm, Thermo Scientific). Eluents were 0.1% FA in water and 0.1% FA in acetonitrile. Mass spectrometry was performed using a micrOTOF-QII (Bruker Daltonik).

[0370] Recorded LC-ESI-MS spectra were internally recalibrated based on the theoretical mass of liraglutide. Extracted ion chromatograms (EICs) were generated for the compounds shown in Figure 1. Compounds observed in the EICs were integrated and intensities were normalized to a compound observed at 382.86 m / z (unknown, not observed in the blank run but specific for the digest). The relative intensity of each compound is shown in arbitrary units.

[0371] Digestion of liraglutide and compound 7 with DPP-IV produced different liraglutide fragments (Figure 1): liraglutide AA9-37 (EGTFTSDV SSYLEGQAAK EFIAWLVRGR G (SEQ ID NO: 5)), liraglutide AA13-37 (TSDV SSYLEGQAAK EFIAWLVRGR G (SEQ ID NO: 6)), and liraglutide AA25-37 (AK EFIAWLVRGR G (SEQ ID NO: 7)). Figure 2 shows the results of a first test run of digestion performed at pH 7.6 with 50 mU / mL DPP-IV at 37°C for 15 hours. Here already two liraglutide fragments were observed: liraglutide AA9-37 and liraglutide AA13-37. The third fragment (liraglutide AA25-37) was not yet observed in this sample. In a final experiment, the pH was lowered to 7.4 to reduce the release of PEGylated compound 7.

[0372] The proteolytic stability of liraglutide and compound 7 was measured by LC-ESI-MS. Figure 3 shows exemplary data of extracted ion chromatogram (EIC) traces of full-size liraglutide and liraglutide fragments in samples after 96 h of digestion with DPP-IV at pH 7.4 and 37 °C. Peaks observed in the EIC were integrated, normalized, and reported in arbitrary units.

[0373] Figure 4 shows the concentration of non-PEGylated liraglutide after digestion with DPP-IV for the two samples. Liraglutide has a half-life of approximately 25 to 35 hours. Compound 7 showed an increase in non-PEGylated liraglutide over the first 34 hours, generated by the release of PEGylation at a slightly alkaline pH. After 34 hours, the released liraglutide in the compound 7 samples showed a slower decline in concentration compared to the initial 34 hours of liraglutide. This may be partially explained by a decrease in enzyme activity after incubation at 37°C, although control studies of unmodified liraglutide indicate that significant enzyme activity would still have been present. Thus, these results appear to indicate a decrease in the proteolytic cleavage of PEG-liraglutide. These results indicate that compound 7 has a much higher proteolytic stability compared to liraglutide.

[0374] Figure 5 shows the concentration of liraglutide fragments after digestion of liraglutide by DPP-IV. Apparently, liraglutide was first digested into liraglutide AA9-37 and liraglutide AA13-37. Then, during digestion, a third liraglutide fragment (liraglutide AA25-37) was generated from the digestion of the first two liraglutide fragments, which showed a decrease after 25-35 hours.

[0375] Figure 6 shows the concentration of liraglutide fragments after digestion of compound 7 with DPP-IV. Here, digestion with DPP-IV produced mainly liraglutide AA9-37. This observation suggests that compound 7 was digested differently from liraglutide. Here, the production of liraglutide AA13-37 and liraglutide AA25-37 was significantly reduced.

[0376] FIG. 7 shows the concentration of the sum of all detected liraglutide fragments after digestion of liraglutide and compound 7 with DPP-IV (see also Tables 1 and 2). The apparent decrease in digestion products in sample liraglutide after 34 hours is most likely due to the liraglutide fragments being further digested into smaller fragments that were not detected by the method. The higher proteolytic stability of compound 7 is highly significant in the first 24 hours. After 24 hours, liraglutide shows about 5 times more digestion products than an equimolar sample of compound 7. After 96 hours, compound 7 shows a higher concentration of observed digestion products. This is most likely due to the fact that the sample liraglutide was further digested into smaller fragments that were not analyzed by the method. The actual concentration of digestion products was most significantly higher for sample liraglutide. This was supported by the fact that liraglutide showed less full-length liraglutide after 96 hours, as shown in FIG. 4. Table 1. Concentration of liraglutide in arbitrary units and the sum of all observed liraglutide fragments for liraglutide (SEQ ID NO: 3, PQ001-2018-001) and compound 7 (PEG-liraglutide, PQ001-2018-003) after digestion with 50 mU / mL DPP-IV in 10 mM Na2HPO4, pH 7.4 at 37°C. [Table 1] [Table 2]

[0377] The proteolytic stability of compound 7 was significantly higher than that of liraglutide. After 24 hours, liraglutide showed approximately 5-fold more digestion products than an equimolar sample of compound 7. Over time, compound 7 showed loss of PEGylation and, as a consequence, increased production of digestion products. However, after 96 hours, compound 7 still showed approximately 7-8-fold more liraglutide under the conditions described.

[0378] In a separate experiment, liraglutide (SEQ ID NO: 3) and compound 7 were successfully digested in vitro with pepsin and analyzed by mass spectrometry using MALDI-TOF-MS. The spectrum of pepsin-digested compound 7 was compared to intact compound 7 and pepsin-digested liraglutide (SEQ ID NO: 3). From these comparisons, it was determined that the N-terminus of liraglutide was the PEGylation site for compound 7. Additionally, the significantly lower intensity for the N-terminal peptide of compound 7 confirmed that the N-terminus was protected by PEGylation.

[0379] In summary, compound 7 provides increased proteolytic stability and longer half-life of liraglutide compared to conjugates of liraglutide with standard fatty acyl modifications (e.g., γ-Glu-palmitoyl liraglutide modification, SEQ ID NO: 3). In contrast to γ-Glu-fatty acyl modifications, because the PEGylation site in compound 7 is in the vicinity of the normal plasma proteolytic site of liraglutide, compound 7 exhibits mechanistically different plasma degradation (proteolysis) and is not otherwise "protected" or "shielded" from proteolysis in any other form of liraglutide. In fact, the γ-Glu acyl tail modification is not necessary for compound 7 to provide increased proteolytic stability of the polypeptide (although acyl-modified GLP polypeptides may still be used in the conjugates of the present disclosure). The GLP polypeptide (e.g., liraglutide) without the acyl tail is in its native form after release from the conjugate, which advantageously leads to increased hydrophilicity, better solubility, and reduced side effects associated with fatty acyl modifications. Thus, the conjugates provided herein are capable of releasing the native ("biobetter") form of GLP.

[0380] In addition, compound 7 was analyzed by RP-HPLC and determined to be about 97% pure.

[0381] In another experiment, a cell-based bioactivity assay (cAMP Hunter™ Liraglutide Bioassay Kit, DiscoverX) was used to evaluate the biological activity of various amounts of liraglutide (SEQ ID NO: 3) and compound 7. An increase in biological activity was detected with increasing amounts of liraglutide (SEQ ID NO: 3), but the biological activity of compound 7 remained low even with increasing amounts (Figure 9). In another experiment, compound 7 was incubated in rat plasma at 37°C (pH 7.4) for 0, 6, 24, 48, and 76 hours. After each time point, the material was tested for the biological activity of any liraglutide released from compound 7 using a cell-based bioactivity assay (cAMP Hunter™ Liraglutide Bioassay Kit, DiscoverX). Biologically active liraglutide released from compound 7 was detected (Figure 10). These results demonstrate that compound 7 has the ability to function as a prodrug in mammals (e.g., humans) and remains inactive compared to liraglutide (SEQ ID NO: 3) until liraglutide is released from the PEGylated moiety of compound 7.

[0382] Example 12 - In vivo performance of compound 7 A stock solution of liraglutide (SEQ ID NO: 3) was prepared by dissolving liraglutide in 10 mM Na2HPO4 (pH 7.4) at a concentration of 10 mg / mL. A stock solution of compound 7 was prepared by dissolving compound 7 in 50 mM ammonium acetate (NH4Ac) buffer (pH 4.5) at a concentration of 10 mg / mL. Before administration to animals, the stock solution was dissolved in PBS (pH 7.4) to a final concentration (5.8 nmol / kg).

[0383] Two groups of six Sprague Dawley rats were used each. The first group (Group 1) received liraglutide (SEQ ID NO: 3) at a dose of 5.8 nmol / kg, administered intravenously in a volume of 1 mL / kg. The second group (Group 2) received Compound 7 at a dose of 5.8 nmol / kg, administered intravenously in a volume of 1 mL / kg. All injections were tail vein bolus injections over 15 seconds.

[0384] Blood samples were collected from the sublingual vein into EDTA precoated vials. Eight blood samples containing 200 μL of blood were collected from each rat over a 48-hour period (pre-dose, 0.08, 1, 3, 6, 24, 30, and 48 hours). Samples were centrifuged at 4500 g for 5 minutes and 100 μL of plasma was transferred to a new 1.5 mL vial. A fixed volume of 0.5 M ammonium acetate was added to bring the plasma to pH 5.5. After acidification, samples were stored at -80°C until analysis. The levels of liraglutide in plasma from both groups were determined using a highly sensitive GLP-1 ELISA kit (Merck EZGLPHS-35K), while the amount of active liraglutide in the samples was measured using a cell-based bioactivity assay.

[0385] The amount of liraglutide measured by ELISA in pooled samples for each time point in group 1 was plotted compared to the amount of total and free liraglutide measured by ELISA in pooled samples for each time point in group 2 (Figure 11). Similarly, the concentration of active liraglutide (nmol / L) measured in individual samples by activity assay for group 1 was compared to that measured for group 2 (Figure 12). These results demonstrate that compound 7 is more stable than liraglutide (SEQ ID NO: 3), has a longer half-life than liraglutide (SEQ ID NO: 3) (7.3 hours for compound 7 vs. 2.9 hours for non-PEGylated liraglutide), and may function like a prodrug. These results also confirm the biological activity of liraglutide released from compound 7 and demonstrate that compound 7 can be used as a once-weekly treatment in type 2 diabetes patients.

[0386] Taken together, the results provided herein demonstrate that drugs (e.g., liraglutide) conjugated to PEG as described herein can be formulated into prodrugs that have little or no biological activity until the drug is released from PEG. This can allow for lower adverse side effects in drug treatment due to lower fluctuations in plasma concentration during the dosing interval. The results provided herein also demonstrate that drugs (e.g., liraglutide) can be linked to PEG as described herein to increase the stability of the drug against degradation by enzymes such as dipeptidyl peptidase IV (DPP-IV). In addition, the results provided herein demonstrate that drugs (e.g., liraglutide) can be linked to PEG as described herein to provide controlled release of the drug with full biological activity. The linkers provided herein can allow for the selection of a desired release time or a desired half-life of the administered drug.

[0387] Example 13. Evaluation of various cleavable groups The multi-step cleavage of the phosphotriester bond and the release of the free drug starts with the hydrolysis of the functional group E. This is usually the rate-limiting step, since all subsequent steps are much faster. In this example, the carbamates obtained from 2'-aminouridine and chloroformates of different β-elimination protecting groups, as presented in Example 15, were dissolved in acetonitrile, and 200 μL of such solution was added to 0.3 M TRIS buffer (PBS) pH 8.0 (1.8 mL). Following this, 3'-azidothymidine, used as an HPLC internal standard reference substance, was immediately added and the sample was incubated at 37 ° C. Samples of this mixture withdrawn at different time points were analyzed to monitor the disappearance of the starting carbamate and the formation of 2'-aminouridine. The results obtained at pH 8.0 can be recalculated for pH 7.4 (physiological conditions) by simply multiplying by 4 (i.e., the decrease in OH concentration).

[0388] The results of these studies are presented in the table below. [ka]

[0389] Specific Embodiments In some embodiments, this document provides compounds of Formula (I) and Formula (II), as well as pharmaceutical compositions and methods of using these compounds, as described in paragraphs 1-126.

[0390] A compound of the first formula (I), [ka] or a pharma- ceutically acceptable salt thereof, The aliphatic portion is a polymer, R P , and Polymer-L-(CH2) m - and polymer-L-(CH2-CH2-O) p -(CH2) m -, R P But, with any substitution C 1-6 Alkyl, optionally substituted C 1-3 Alkyl-O-(CH2-CH2-O) p -(CH2) m - and optionally substituted C 3-7 cycloalkyl; L is a linking group; m and p are each independently an integer from 1 to 10; D is a residue of a GLP-1 polypeptide or an analog thereof; Z 1 is O, S, and N(R N ), Z 3 is O and N(R N ) or Z 3 does not exist, A is O or N, and when A is O, R 3 does not exist, R N is H and optionally substituted C 1-6alkyl, R 3 But H and C 1-6 alkyl; or R 3 and R 1 But A and R 1 together with the carbon atom to which it is attached form an optionally substituted 4- to 7-membered aliphatic heterocyclic ring; or R 3 and R 2 But, A, R 1 The carbon atom to which is bonded, and R 2 together with the carbon atom to which it is attached form an optionally substituted 4- to 8-membered aliphatic heterocyclic ring; M A is a self-immolative group having any one of the formulae (a) to (i), [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 indicates the point of attachment to R 1 and R 2 are independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 aryl, and optionally substituted 5- to 14-membered heteroaryl; Or, R 1 and R 2 are bonded together with the carbon atom to which they are attached to an optionally substituted C 3-7 Cycloalkyl rings, optionally substituted 4- to 7-membered aliphatic heterocyclic rings, optionally substituted C 6-10 aryl, or an optionally substituted 5-14 membered heteroaryl; Or, R 1 and R 2 are linked together to form a ribose ring system, R 7 and R 8 but independently, H and C 1-6 alkyl, The compound or a pharma- ceutically acceptable salt thereof, wherein E is a cleavable moiety.

[0391] A compound of the second formula (II), [ka] or a pharma- ceutically acceptable salt thereof, The aliphatic portion is a polymer, R P , and Polymer-L-(CH2) m - and polymer-L-(CH2-CH2-O) p -(CH2) m -, R P But, with any substitution C 1-6 Alkyl, optionally substituted C 1-3 Alkyl-O-(CH2-CH2-O) p -(CH2) m - and optionally substituted C 3-7 cycloalkyl; L is a linking group; m and p are each independently an integer from 1 to 10; D is the residue of a biologically active drug; Z 1 is O, S, and N(R N ), Z 3 is O and N(R N ) or Z 3 does not exist, Z 4 is selected from O and S; A is O and N(R N ), R N is H and optionally substituted C 1-4 alkyl, M A is a diradical selected from i. A self-immolative group having any one of the formulae (a) to (i): [ka] And ii. A stable diradical selected from any one of formulas (j) to (l): [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 indicates the point of attachment to R 1 and R 2 are independently hydrogen, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 aryl, and optionally substituted 5- to 14-membered heteroaryl; Or, R 1 and R 2 are bonded together with the carbon atom to which they are attached to an optionally substituted C 3-7 Cycloalkyl rings, optionally substituted 4- to 7-membered aliphatic heterocyclic rings, optionally substituted C 6-10 aryl, or an optionally substituted 5-14 membered heteroaryl; Or, R 1 and R 2 are linked together to form a ribose ring system, R 7 and R 8 are independently H, C 1-6 Alkyl, amino, (C 1-6 Alkyl)amino, di-(C 1-6 alkyl)amino, acylamino, and protected amino groups; The compound or a pharma- ceutically acceptable salt thereof, wherein E is a cleavable moiety.

[0392] Item 3: The aliphatic portion is a polymer, R P and selected from the group of the following formulas: Polymer-L-(CH2) m - R P But, with any substitution C 1-6Alkyl and optionally substituted C 3-7 cycloalkyl, and m is an integer from 1 to 10.

[0393] Item 4 The aliphatic moiety has the formula: polymer-L-(CH2) m The compound according to any one of items 1 to 3, wherein the R is a - group.

[0394] Item 5: The compound according to any one of items 1 to 4, wherein L is a linking group containing heterocycloalkylene or heteroarylene.

[0395] Item 6: The compound according to any one of items 1 to 5, wherein L is a linking group containing succinimide or triazole.

[0396] The seventh item, L, is a linking group having any one of the following formulae: [ka] During the ceremony, [ka] 7. The compound according to any one of claims 1 to 6, wherein indicates the point of attachment of the linking group to the polymer or to the CH2 group.

[0397] Item 8 The linking group L is a linking group of the following formula: [ka] During the ceremony, [ka] 8. The compound according to any one of claims 1 to 7, wherein indicates the point of attachment of the linking group to the polymer or to the CH2 group.

[0398] Item 9: The linking group L is represented by the formula (L 1 ) group, [ka] wherein ring C is an optionally substituted C 8-16 selected from the group consisting of cycloalkyl and optionally substituted 8- to 16-membered heterocycloalkyl; [ka] 9. The compound according to any one of claims 1 to 8, wherein indicates the point of attachment of the linking group to the polymer or to the CH2 group.

[0399] The 10th term (L 1 10. The compound according to any one of claims 1 to 9, wherein the group: [ka]

[0400] Item 11: The compound according to any one of items 1 to 10, wherein m is an integer of 1 to 6.

[0401] Item 12: The compound according to any one of items 1 to 11, wherein m is an integer of 1 to 4.

[0402] Item 13. The compound according to any one of items 1 to 12, wherein the aliphatic moiety is a polymer.

[0403] Item 14. The compound according to any one of items 1 to 13, wherein the polymer is selected from the group consisting of poly(alkylene glycols), poly(oxyethylated polyols), poly(olefinic alcohols), poly(α-hydroxy acids), poly(vinyl alcohols), polyoxazolines, and copolymers thereof.

[0404] Item 15. The compound according to any one of items 1 to 14, wherein the polymer is polyethylene glycol.

[0405] Item 16. The compound according to any one of items 1 to 15, wherein the polyethylene glycol is linear.

[0406] Item 17. The compound according to any one of items 1 to 16, wherein the polyethylene glycol is branched.

[0407] Item 18. The compound according to any one of items 1 to 17, wherein the polyethylene glycol has an average molecular weight of about 500 Da to about 40,000 Da.

[0408] Item 19. The compound according to any one of items 1 to 18, wherein the polyethylene glycol has an average molecular weight of about 1,000 Da to about 30,000 Da.

[0409] Item 20. The compound according to any one of items 1 to 19, wherein the polyethylene glycol has an average molecular weight of about 1,000 Da to about 20,000 Da.

[0410] Item 21. The compound according to any one of items 1 to 20, wherein the polyethylene glycol has an average molecular weight of about 5,000 Da to about 20,000 Da.

[0411] Item 22. The compound according to any one of items 1 to 21, wherein the polyethylene glycol has the following structural formula: [ka]

[0412] Item 23: The compound according to any one of items 1 to 22, wherein n is an integer of 1 to 1,000.

[0413] Item 24: The compound according to any one of items 1 to 23, wherein n is an integer of 1 to 800.

[0414] Item 25: The compound according to any one of items 1 to 24, wherein n is an integer of 1 to 300.

[0415] Item 26: The compound according to any one of items 1 to 25, wherein n is an integer of 1 to 100.

[0416] Item 27. The compound according to any one of items 1 to 26, wherein n is selected from 10, 20, 50, 100, 200, 250, 300, 500, 600, and 1000.

[0417] Item 28: Aliphatic moiety, R P 28. The compound according to any one of items 1 to 27,

[0418] Section 29R P But, with any substitution C 1-6 29. The compound according to any one of items 1 to 28, wherein the compound is alkyl.

[0419] Section 30R P 30. The compound according to any one of items 1 to 29, wherein is isopropyl.

[0420] Section 31R P The compound according to any one of items 1 to 30, wherein is cyanoethyl.

[0421] Section 32R P is selected from any one of the groups of the following formulae: [ka]

[0422] Section 33R P is selected from any one of the groups of the following formulae:

[0423] [ka]

[0424] Section 35R P is selected from any one of the following formulae: [ka]

[0425] Section 36Z 1 But S and M A is a self-immolative group of formula (a), [ka] In the formula, x is Z 1 indicates the point of attachment to Z 3 36. The compound according to any one of clauses 1 to 35, showing the point of attachment to.

[0426] Section 37R 7 and R 8 is independently selected from H and methyl.

[0427] Section 38R 1 and R 2 and each are hydrogen.

[0428] Section 39R 1 and R 2 But together, C 3-7 The compound according to any one of items 1 to 38, which forms a cycloalkyl ring.

[0429] Section 40C 3-7 40. The compound according to any one of clauses 1-39, wherein the cycloalkyl ring is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0430] Section 41R 1 and R 2 and together form a 4- to 7-membered aliphatic heterocyclic ring.

[0431] Item 42: The compound according to any one of items 1 to 41, wherein the 4- to 7-membered aliphatic heterocyclic ring is selected from the group consisting of pyrrolidine, piperidine, tetrahydrofuran, and tetrahydropyran.

[0432] Section 43R 1 and R 2 together form a ribose ring system of a ribonucleoside.

[0433] Section 44R 1 and R 2 together form a ribose ring system of the formula: [ka] 44. The compound according to any one of claims 1 to 43, wherein either a represents a point of attachment to O and b represents a point of attachment to A, or a represents a point of attachment to A and b represents a point of attachment to O, and W is selected from the group consisting of H, an acyl group, and a protecting group.

[0434] Item 45. The compound according to any one of items 1 to 44, wherein the nucleobase is selected from the group consisting of adenine, cytosine, guanine, thymine, uracil, and other natural and unnatural nucleobases.

[0435] Item 46. The compound according to any one of items 1 to 45, wherein the nucleobase is selected from the group consisting of adenine, cytosine, guanine, thymine, and uracil.

[0436] Item 47. The compound according to any one of items 1 to 46, wherein the nucleobase is selected from the group consisting of 5-methylcytosine, pseudouridine, dihydrouridine, inosine, 7-methylguanosine, hypoxanthine, and xanthine.

[0437] Item 48. The compound according to any one of items 1 to 47, wherein the nucleobase comprises a fluorescent group.

[0438] Item 49. The compound according to any one of items 1 to 48, wherein the nucleobase comprises a polymer.

[0439] Section 50R 1 and R 2together form a ribose ring system of the formula: [ka]

[0440] Section 51R 1 and R 2 together form a ribose ring system of the formula: [ka]

[0441] Item 52: The compound according to any one of items 1 to 51, wherein A is O.

[0442] Section 53A of the NR 3 Item 53. The compound according to any one of items 1 to 52, wherein

[0443] Section 54R 3 and R 1 But A and R 1 together with the carbon atom to which it is attached form an optionally substituted 4- to 7-membered aliphatic heterocyclic ring.

[0444] Item 55: The 4- to 7-membered aliphatic heterocyclic ring is selected from the group consisting of: [ka] where x indicates the point of attachment to E and y indicates R 1 indicates the point of attachment to the carbon atom to which it is bonded.

[0445] Section 56R 3 and R 2 But, A, R 1 The carbon atom to which is bonded, and R 2together with the carbon atom to which it is attached form an optionally substituted 4-8 membered aliphatic heterocyclic ring.

[0446] Item 57. The compound according to any one of items 1 to 56, wherein A is NH.

[0447] 58A is N(C 1-6 58. The compound according to any one of items 1 to 57, wherein R is an alkyl group.

[0448] 59. The compound according to any one of claims 1 to 58, wherein E is cleavable by an enzyme selected from the group consisting of esterases, specific or non-specific peptidases, reductases, oxidases, glycosidases, hydrolases, glycosyltransferases, and transaminases.

[0449] 60. The compound according to any one of claims 1 to 59, wherein E is cleavable by an enzyme selected from the group consisting of esterases, reductases, oxidases, glycosides, hydrolases, and glycosyltransferases.

[0450] 61. The compound according to any one of clauses 1 to 60, wherein E is non-enzymatically cleavable at acidic or physiological pH.

[0451] Item 62. The compound according to any one of items 1 to 61, wherein E is an acyl group, an O-methyl-acyl group, a methylazide group, a sugar residue, a protected acetal, or a carbonate ester.

[0452] 63. The compound according to any one of the preceding claims, wherein E is cleavable by a reductase enzyme.

[0453] Item 64. The compound according to any one of items 1 to 63, wherein A is O and E is a group of the following formula: [ka]

[0454] 65. The compound according to any one of the preceding claims, wherein E contains a dithio group that is cleavable by a biological thiol.

[0455] 66. The compound according to any one of the preceding claims, wherein E is cleavable by glutathione.

[0456] Item 67 E is a group of any one of the following formulae: [ka] In the formula, R E But, C 1-6 67. The compound according to any one of the preceding claims, wherein the aryl group is selected from the group consisting of alkyl and benzyl.

[0457] Item 68. The compound according to any one of items 1 to 67, wherein A is O and E is a group of the following formula: [ka]

[0458] 69. The compound according to any one of clauses 1 to 68, wherein E is cleavable by a glycoside hydrolase enzyme.

[0459] Item 70. The compound according to any one of items 1 to 69, wherein E is a sugar residue selected from glucose, galactose, mannose, and glucuronic acid.

[0460] 71. The compound according to any one of claims 1 to 70, wherein E is cleavable by an esterase enzyme.

[0461] Item 72. The compound according to any one of items 1 to 71, wherein E is selected from an acyl group, a carbonate ester, and an O-methyl-acyl ester.

[0462] 73. The compound according to any one of clauses 1 to 72, wherein E is cleavable by hydrolysis at physiological pH.

[0463] Item 74: The compound according to any one of items 1 to 73, wherein E is an acyl group.

[0464] Section 75A of the NR N or NR 3 and E is a cleavable moiety of the formula: [ka] During the ceremony, R 9 H, optionally substituted C 6-10 Aryl and optionally substituted C 1-6 alkyl, R 10 and R 11 are independently H, CN, NO2, and COR 12 , SOR 12 or SO2R 12 , optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 aryl, and optionally substituted 5- to 14-membered heteroaryl; R 10 and R 11 together with the carbon atom to which they are attached, one or more optionally substituted C 6-10 Optionally substituted C fused to an aryl ring 3-7 forming a cycloalkyl ring, R 12 But, with any substitution C 1-6 Alkyl and optionally substituted C 6-10 aryl;

[0465] 76. A is NH and R 9 is H and optionally substituted C 6-10 76. The compound according to any one of the preceding claims, wherein the compound is selected from aryl.

[0466] Item 77 E is a cleavable moiety of any one of the following formulae (E-1) to (E-12) and (E-37) to (E-42): [ka] JPEG0007675648000198.jpg44166 In the formula, any one of the phenyl rings of the formulas (E-1) to (E-12), (E-37), or (E-39) to (E-41) is C 1-10 Alkyl, C 1-10 Haloalkyl, C 1-10 77. The compound of any one of clauses 1-76, optionally substituted with 1, 2, 3, 4, or 5 substituents selected from alkoxy, OH, NO2, CN, halogen, and acyl.

[0467] 78. The compound according to any one of claims 1 to 77, wherein E is a cleavable moiety of any one of formulas (E-1) to (E-12), (E-37), or (E-39) to (E-41).

[0468] Item 79: A compound according to any one of items 1 to 78, wherein any one of the phenyl rings of formula (E-1) to (E-12), (E-37), or (E-39) to (E-41) is optionally substituted with 1, 2, 3, or 4 substituents selected from F, Cl, CN, acetyl, NO2, and CF3.

[0469] Item 80 E is any one of the groups of the following formulae (E-13) to (E-36), [ka] JPEG0007675648000200.jpg75166In the formula, R is C 1-6 80. The compound according to any one of the preceding claims, wherein R is alkyl.

[0470] 81. The compound according to any one of the preceding claims, wherein E is cleavable at acidic pH.

[0471] Item 82. The compound according to any one of items 1 to 81, wherein E is a group selected from acetals, ortho-esters, and substituted triphenylmethyl ethers.

[0472] 83. The compound according to any one of the preceding claims, wherein E is selected from tetrahydrofuranyl, 4-methoxytetrahydropyran-4-yl, 1,5-dicarbo-methoxypentanyl, methoxyisopropyl acetal, methoxycyclohexenyl acetal, dimethoxytrityl, trimethoxytrityl, and pixyl.

[0473] Item 84: The cleavable moiety E is a member of the formula (L E ) group to A, [ka] 84. The compound according to any one of the preceding claims, wherein a represents the point of attachment to A and b represents the point of attachment to E.

[0474] 85. The compound according to any one of clauses 1 to 84, wherein clause D is a residue of a GLP-1 polypeptide.

[0475] 86. The compound according to any one of clauses 1 to 85, wherein clause D is a residue of a GLP-1 polypeptide analogue.

[0476] Item 87. The compound according to any one of items 1 to 86, wherein the GLP-1 polypeptide analogue is liraglutide.

[0477] Item 88: The compound of formula (I) has any one of the following formulae: [ka] 88. The compound according to any one of items 1 to 87, which is JPEG0007675648000203.jpg176166 or a pharma- ceutically acceptable salt thereof.

[0478] Item 89: The compound of formula (II) according to any one of items 2 to 87, having the formula (II-1): [ka] or a pharma- ceutically acceptable salt thereof.

[0479] Item 90: The compound of formula (II) according to any one of items 1 to 89, wherein the compound has the formula (II-2): [ka] or a pharma- ceutically acceptable salt thereof.

[0480] Item 91: The compound according to any one of items 1 to 90, wherein the compound of formula (II) has the formula (II-3): [ka] or a pharma- ceutically acceptable salt thereof.

[0481] Item 92: The compound according to any one of items 1 to 91, wherein the compound of formula (II) has the formula (II-4): [ka] or a pharma- ceutically acceptable salt thereof.

[0482] Item 93: The compound of formula (II) according to any one of items 1 to 92, wherein the compound has any one of the following formulae (II-5) to (II-7): [ka] or a pharma- ceutically acceptable salt thereof, A compound or a salt thereof, wherein when the compound has formula II-7, A is O.

[0483] Item 94: The compound of formula (II) according to any one of items 1 to 93, wherein the compound has the formula (II-8): [ka] or a pharma- ceutically acceptable salt thereof.

[0484] Item 95: The compound according to any one of items 1 to 94, wherein the compound of formula (II) has any one of the following formulae: [ka] JPEG0007675648000211.jpg62166, or a pharma- ceutically acceptable salt thereof.

[0485] Item 96: The compound of formula (II) according to any one of items 1 to 95, having the formula (II-10a): [ka] or a pharma- ceutically acceptable salt thereof.

[0486] Item 97: The compound of formula (II) has the formula (II-10), [ka] or a pharma- ceutically acceptable salt thereof.

[0487] Item 98: The compound according to any one of items 1 to 97, wherein the compound of formula (II) has the formula (II-11a): [ka] or a pharma- ceutically acceptable salt thereof.

[0488] Item 99: The compound according to any one of items 1 to 98, wherein the compound of formula (II) has the formula (II-11): [ka] or a pharma- ceutically acceptable salt thereof.

[0489] The compound according to any one of items 1 to 99, wherein the compound of formula (II) has the formula (II-12): [ka] or a pharma- ceutically acceptable salt thereof.

[0490] Item 101: The compound according to any one of items 1 to 100, wherein the compound of formula (II) has the formula (II-14): [ka] or a pharma- ceutically acceptable salt thereof.

[0491] Item 102: The compound according to any one of items 1 to 101, wherein the compound of formula (II) has the formula (II-15): [ka] or a pharma- ceutically acceptable salt thereof.

[0492] Item 103: The compound of formula (II) has the formula (II-16): [ka] or a pharma- ceutically acceptable salt thereof.

[0493] Section 104R P But, C 1-6 Item 4. The compound according to any one of items 1 to 103, wherein the aryl group is alkyl.

[0494] Section 105R P The compound according to any one of items 1 to 104, wherein is isopropyl.

[0495] Section 106R P The compound according to any one of items 1 to 105, wherein is cyanoethyl.

[0496] Item 107: The compound of formula (I) [ka] Item 107. The compound according to any one of items 1 to 106, or a pharma- ceutically acceptable salt thereof, wherein liraglutide is a residue of liraglutide.

[0497] Item 108: The compound of formula (I) [ka] Item 108. The compound according to any one of items 1 to 107, or a pharma- ceutically acceptable salt thereof, wherein liraglutide is a residue of liraglutide, or a salt thereof.

[0498] Item 109: The compound of formula (I) [ka] Item 109. The compound according to any one of items 1 to 108, or a pharma- ceutically acceptable salt thereof, wherein liraglutide is a residue of liraglutide.

[0499] The compound of formula (I) according to paragraph 110, [ka] Item 109. The compound according to any one of items 1 to 109, or a pharma- ceutically acceptable salt thereof, wherein liraglutide is a residue of liraglutide.

[0500] Item 111: The compound of formula (I) [ka] Item 111. The compound according to any one of items 1 to 110, or a pharma- ceutically acceptable salt thereof, wherein liraglutide is a residue of liraglutide.

[0501] The compound of formula (I) according to item 112, [ka] Item 112. The compound according to any one of items 1 to 111, or a pharma- ceutically acceptable salt thereof, wherein liraglutide is a residue of liraglutide.

[0502] Item 113: The compound of formula (I) [ka] Item 113. The compound according to any one of items 1 to 112, or a pharma- ceutically acceptable salt thereof, wherein liraglutide is a residue of liraglutide, or a salt thereof.

[0503] The compound of item 114 is [ka] Item 114. The compound according to any one of items 1 to 113, or a pharma- ceutically acceptable salt thereof, wherein U is uracil, which is not:

[0504] Item 115: The compound according to any one of items 1 to 114, wherein E is not (E-38).

[0505] The compound of item 116 is [ka] Item 116. The compound according to any one of items 1 to 115, wherein:

[0506] The compound of item 117 is [ka] Item 117. The compound according to any one of items 1 to 116, wherein:

[0507] The compound of item 118 is [ka] Item 118. The compound according to any one of items 1 to 117, wherein:

[0508] Item 119: A compound according to any one of items 1 to 118, wherein the drug (e.g., liraglutide, a GLP-1 polypeptide, or an analog thereof) when conjugated to a compound of formula (I) or formula (II) is inactive or has a weaker biological activity compared to the drug in its free, unconjugated form, and the drug regains its biological activity after being released from the compound of formula (I) or formula (II).

[0509] Item 120. A pharmaceutical composition comprising the compound according to any one of items 1 to 119 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier.

[0510] Clause 121: A method for treating a disease or condition in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound described in any one of clauses 1 to 120 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition described in clause 116.

[0511] Item 122. The method of item 117, wherein the disease or condition is selected from diabetes and obesity.

[0512] Item 123: A compound according to any one of items 1 to 122, having the following formula: [ka] or a pharma- ceutically acceptable salt thereof, the method comprising: (i) reacting a compound of the formula: [ka] formula HZ 3-D with a GLP-1 polypeptide or an analog thereof.

[0513] 124. Compounds of the following formula: [ka] (i) a compound of the formula: 1 is a protecting group), [ka] Obtaining a compound of formula [ka] (II) reacting the compound obtained in step (i) with a compound containing a leaving group.

[0514] Compounds of the following formula: [ka] (i) reducing a compound of the formula: [ka] Obtaining a compound of formula [ka] (II) reacting the compound obtained in step (i) with a compound containing a leaving group.

[0515] 126. The method of any one of claims 1 to 125, wherein D is a residue of liraglutide.

[0516] Other embodiments Although the present application has been described in conjunction with its detailed description, it should be understood that the foregoing description is illustrative and is not intended to limit the scope of the application, which is defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. The present invention includes the following embodiments. [Claim 1] A compound of formula (I), [ka] or a pharma- ceutically acceptable salt thereof, The aliphatic moiety is a polymer, R P , and Polymer-L-(CH 2 ) m - and polymer-L-(CH 2 -CH 2 -O) p -(CH 2 ) m -, R P But, with any substitution C 1-6 Alkyl, optionally substituted C 1-3 Alkyl-O-(CH 2 -CH 2 -O) p -(CH 2 ) m - and optionally substituted C 3-7 cycloalkyl; L is a linking group; m and p are each independently an integer from 1 to 10; D is a residue of a GLP-1 polypeptide or an analog thereof; Z 1 is O, S, and N(R N ), Z 3 is O and N(R N ) or Z 3 does not exist, A is O or N, and when A is O, R 3 does not exist, R N is H and optionally substituted C 1-6 alkyl, R 3 But H and C 1-6 alkyl; or R 3 and R 1 But A and R 1 together with the carbon atom to which it is attached form an optionally substituted 4- to 7-membered aliphatic heterocyclic ring; or R 3 and R 2 But, A, R 1 The carbon atom to which is bonded, and R 2 together with the carbon atom to which it is attached form an optionally substituted 4- to 8-membered aliphatic heterocyclic ring; M A is a self-immolative group having any one of the formulae (a) to (i),

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

Claims

1. A compound of formula (I), 【Chemistry 1A】 or a pharma- ceutically acceptable salt thereof, X １ is polyethylene glycol, X ２ is the nucleobase, W is selected from the group consisting of H, an acyl group, and a protecting group; D is a GLP-1 polypeptide or an analog thereof, said GLP-1 polypeptide or an analog thereof being liraglutide or a fragment thereof, said fragment having the amino acid sequence of SEQ ID NO: 4, 5, 6 or 7; R ７ and R ８ independently, H and C １－６ alkyl, E is a cleavable moiety of any one of the following formulae (E-1) to (E-12) and (E-37) to (E-42): 【Chemistry 10】 In the formulae (E-1) to (E-12), (E-37) or (E-39) to (E-41), any one of the phenyl rings is C １－１０ Alkyl, C １－１０ Haloalkyl, C １－１０ Alkoxy, OH, NO ２ or a pharma- ceutically acceptable salt thereof, optionally substituted with 1, 2, 3, 4, or 5 substituents selected from: CN, halogen, and acyl.

2. The compound of claim 1 , wherein the polyethylene glycol is linear.

3. The compound of claim 1 , wherein the polyethylene glycol is branched.

4. 2. The compound of claim 1 , wherein the polyethylene glycol has the following structural formula: 【Chemistry 6】 (wherein n is an integer from 1 to 1,000).

5. R ７ and R ８ The compound of any one of claims 1 to 4, wherein is independently selected from H and methyl.

6. The compound according to any one of claims 1 to 5, wherein the nucleobase is selected from the group consisting of adenine, cytosine, guanine, thymine and uracil.

7. 7. The compound of any one of claims 1 to 6, wherein E is cleavable by an enzyme selected from the group consisting of esterases, specific or non-specific peptidases, reductases, oxidases, glycosidases, hydrolases, glycosyltransferases, and transaminases.

8. The compound according to any one of claims 1 to 6, wherein E is non-enzymatically cleavable at acidic or physiological pH.

9. The compound according to any one of claims 1 to 8, wherein the GLP-1 polypeptide or analogue thereof is liraglutide.

10. The compound of formula (I) has the formula: 【Chemistry 12A】 or a pharma- ceutically acceptable salt thereof, wherein the substituents are as defined in claim 1. The compound according to any one of claims 1 to 9,

11. The compound of formula (I) 【Chemical 15A】 【change】 or a pharma- ceutically acceptable salt thereof, wherein liraglutide is liraglutide, Ura is uracil, Me is methyl, and PEG is polyethylene glycol.

12. The compound is 【Chemistry 23A】 or a pharma- ceutically acceptable salt thereof, wherein liraglutide is liraglutide and U Ｂｚ is 3-benzoyluracil, U Ｃ１８ teeth 【Chemistry 100】 10. The compound according to any one of claims 1 to 9, wherein Piv is pivaloyl, DMTr is dimethoxytrityl, Me is methyl, PEG is polyethylene glycol, and FMOC is 1-fluorenylethoxycarbonyl.

13. 13. A pharmaceutical composition for treating a disease or condition selected from diabetes and obesity in a subject in need of such treatment, comprising a compound according to any one of claims 1 to 12 or a pharma- ceutically acceptable salt thereof.

14. A compound according to any one of claims 1 to 12, having the following formula: 【Chemistry 26】 or a pharma- ceutically acceptable salt thereof, said method comprising: (i) reacting a compound of the formula: 【Chemistry 27】 Formula H ２ 11. The method of claim 1, comprising reacting a GLP-1 polypeptide or analog thereof with a compound represented by the formula: N-D, wherein LG is a leaving group and the substituents other than LG are as defined in claim 1.

15. The compound of the formula: 【Chemistry 28】 (i) deprotecting a compound of the formula: 【Chemical 29】 Obtaining a compound of formula 【Chemistry 30】 (ii) treating the compound obtained in step (i) with a compound of the formula: 【Chemistry 101】 with a compound containing a leaving group represented by the formula: １ is a protecting group, PG １ The method according to claim 14, wherein the substituents other than are as defined in claim 14.

16. The compound of the formula: 【Chemistry 31】 (i) reducing a compound of the formula: 【Chemistry 32】 Obtaining a compound of formula 【Chemistry 32】 (ii) treating the compound obtained in step (i) with a compound of the formula: 【Chemistry 101】 and reacting the compound represented by the formula: with a compound comprising a leaving group, the compound being represented by the formula:

Images